Establishing an *in vitro* disease model for Fabry Disease using patient specific induced pluripotent stem cell-derived sensory neurons

**Etablierung eines *in vitro* Krankheitsmodells für M. Fabry mittels patienteneigener sensibler Neurone, generiert über induzierte pluripotente Stammzellen**

Doctoral thesis for a doctoral degree

at the Graduate School of Life Sciences,

Julius-Maximilians-Universität Würzburg,

Section Neuroscience

submitted by

Thomas Klein

from

Bamberg

Würzburg 2019
Members of the *Promotionskomitee*:

Chairperson: Prof. Dr. Manfred Gessler

Primary Supervisor: Prof. Dr. Nurcan Üçeyler

Supervisor (Second): PD Dr. Robert Blum

Supervisor (Third): Prof. Dr. Erhard Wishmeyer

Supervisor (Fourth): Prof. Dr. Claudia Sommer

Date of Public Defence: ..............................................................

Date of Receipt of Certificates:
..............................................................
Affidavit

I hereby confirm that my thesis entitled “Establishing an *in vitro* disease model for Fabry Disease using patient specific induced pluripotent stem cell-derived sensory neurons” is the result of my own work. I did not receive any help or support from commercial consultants. All sources and / or materials applied are listed and specified in the thesis.

Furthermore, I confirm that this thesis has not yet been submitted as part of another examination process neither in identical or in similar form.

Place, Date

Signature

Eidesstattliche Erklärung

Hiermit erkläre ich an Eides statt, die Dissertation “Etablierung eines *in vitro* Krankheitsmodells für M. Fabry mittels patienteneigener sensibler Neurone, generiert über induzierte pluripotente Stammzellen” eigenständig, d.h. insbesondere selbstständig und ohne Hilfe eines kommerziellen Promotionsberaters angefertigt und keine anderen als die von mir angegebenen Quellen und Hilfsmittel verwendet zu haben.

Ich erkläre außerdem, dass die Dissertation weder in gleicher noch in ähnlicher Form bereits in einem anderen Prüfungsverfahren vorgelegen hat.

Ort, Datum

Unterschrift
1 Abstract ........................................................................................................................................... 1
2 Zusammenfassung ........................................................................................................ 3
3 Introduction ................................................................................................................................... 5
3.1 Fabry disease ................................................................................................................................. 5
  3.1.1 Genetic background of FD ....................................................................................................... 5
  3.1.2 Small fiber pathology in FD .................................................................................................... 6
  3.1.3 FD-associated pain .................................................................................................................. 6
  3.1.4 Diagnostic criteria for FD ........................................................................................................ 7
  3.1.5 FD-specific and analgesic treatment ....................................................................................... 7
  3.1.6 Pathophysiology of FD pain and small fiber pathology ............................................................ 8
3.2 Induced pluripotent stem cells ....................................................................................................... 9
  3.2.1 Reprogramming mechanism ................................................................................................. 10
  3.2.2 Reprogramming approaches ................................................................................................. 11
  3.2.3 Stem cell niches and differentiation ..................................................................................... 11
  3.2.4 iPSC-based disease and pain models ..................................................................................... 12
3.3 Aim of this study ........................................................................................................................... 13
4 Materials and Methods .................................................................................................................... 14
  4.1 Equipment and reagents ............................................................................................................. 14
  4.2 Patients ....................................................................................................................................... 14
  4.3 Immunocytochemistry (ICC) ..................................................................................................... 15
    4.3.1 Labeling of extracellular targets ......................................................................................... 15
    4.3.2 dSTORM imaging .............................................................................................................. 16
  4.4 Immunohistochemistry ................................................................................................................. 16
  4.5 Imaging setups ............................................................................................................................. 16
    4.5.1 Conventional epifluorescence ........................................................................................... 16
    4.5.2 Phase contrast imaging ........................................................................................................ 17
4.5.3 Super-resolution and confocal imaging ................................................................. 17
4.6 Skin punch biopsy and human dermal fibroblast (HDF) cultivation ................. 17
4.7 Reprogramming of HDF to iPSC and clonal expansion ................................. 18
4.8 Cultivation of iPSC................................................................................................. 18
4.9 Characterization of putative iPSC ..................................................................... 19
4.9.1 Trilineage differentiation .................................................................................. 19
4.9.2 Flow cytometry ............................................................................................... 19
4.9.3 Sanger sequencing .......................................................................................... 20
4.9.4 Mycoplasma detection ..................................................................................... 20
4.10 TK1-iPSC GLA transcriptomics and XCI ......................................................... 20
4.11 Differentiation of iPSC into sensory neurons ................................................. 21
4.12 Functional tests of iPSC-derived sensory neurons ........................................ 22
4.12.1 Incubation with agalsidase-β ....................................................................... 22
4.12.2 Incubation with TNF .................................................................................... 22
4.12.3 Quantification of neuronal Gb3 accumulations ............................................. 22
4.12.4 Confocal Ca²⁺ imaging .................................................................................. 25
4.12.5 Patch clamp analysis ..................................................................................... 25
4.13 Quantitative real-time PCR (qRT-PCR) experiments .................................... 25
4.14 Statistical analysis ............................................................................................. 26
5 Results ...................................................................................................................... 27
5.1 Generation and characterization of one female FD-iPSC line .......................... 27
5.2 Gb3 accumulation in TK1-iPSC and neurons ................................................... 29
5.3 gDNA/cDNA analysis for TK1-iPSC................................................................. 30
5.4 Gb3 accumulations in male skin samples ......................................................... 31
5.5 Generation and characterization of four male FD-PSC lines ............................ 32
5.5.1 mRNA reprogramming of TK8 ..................................................................... 32
5.5.2 Full characterization of TK8 and TK9 iPSC lines .......................................... 33
5.6 Gb3 accumulations in male FD-iPSC lines ....................................................... 37
5.7 Sensory neuron differentiation of iPSC ................................................. 38
  5.7.1 Time course of the differentiation ............................................. 38
  5.7.2 Assesment of cytostatic compounds ........................................... 39
  5.7.3 Marker expression during differentiation phase ........................... 39
  5.7.4 Marker expression on mature neurons - ICC .............................. 41
  5.7.5 TRPV1 labeling using dkTx ..................................................... 43
  5.7.6 Marker expression of mature neurons – qRT-PCR ........................ 44
5.8 Neuronal Gb3 accumulations ............................................................ 45
5.9 Effect of ERT on Gb3 depositions ..................................................... 47
5.10 Effect of TNF on neuronal Gb3 accumulations ................................. 51
5.11 Confocal Ca$^{2+}$ imaging ............................................................... 52
5.12 Patch clamp analysis of mature neurons ........................................ 56
5.13 dSTORM: Proof-of-Principle .......................................................... 57
6 Discussion ............................................................................................. 58
  6.1 Summary of main results ................................................................. 58
  6.2 iPSC-derived sensory neurons as a potent tool in pain research ........ 58
  6.3 Suitability of iPSC from female patients for disease modelling .......... 59
  6.4 iPSC and iPSC-derived sensory neurons from male FD patients ....... 61
  6.5 Pharmacological response and Gb3 accumulations ......................... 61
  6.6 Electrophysiological properties of iPSC-derived sensory neurons ....... 62
  6.7 Labeling of Gb3 and TRPV1 ......................................................... 64
  6.8 Improved sensory differentiation protocol ....................................... 65
  6.9 The diversity of pain in FD and experimental therapies .................... 65
  6.10 Conclusion and outlook ............................................................... 68
7 References .............................................................................................. 70
8 Appendices .............................................................................................. 80
  8.1 Media for cultivation ..................................................................... 80
  8.2 Reagents ......................................................................................... 81
Parts of the results presented in this thesis have been published:


The published manuscript and this thesis contain similar text passages in adapted form in some sections.

The TK1 cell line was generated during the master thesis, and fully characterized during this doctoral thesis:

**Klein, T.** (2016). Generation of patient-derived peripheral sensory neurons via reprogramming and transdifferentiation of human fibroblasts into iPSCs and iNPCs. Master of Science, University of Würzburg.

The control cell line was fully characterized by Katharina Klug during her master thesis:

1 Abstract

Fabry disease (FD) is an X-linked lysosomal storage disorder caused by deficiency of the α-galactosidase A (GLA), leading to intracellular accumulations of globotriaosylceramide (Gb3). Acral burning pain, which can be triggered by heat, fever or physical activity is an early hallmark of FD and greatly reduces patients' quality of life. The pathophysiology of FD pain is unknown and research is hindered by the limited in vivo availability of suitable human biomaterial. To overcome this obstacle, we generated induced pluripotent stem cells (iPSC) from one female and two male patients with a differing pain phenotype, and developed a refined differentiation protocol for sensory neurons to increase reliability and survival of these neurons, serving as an in vitro disease model. Neurons were characterized for the correct neuronal subtype using immunocytochemistry, gene expression analysis, and for their functionality using electrophysiological measurements.

iPSC and sensory neurons from the male patients showed Gb3 accumulations mimicking the disease phenotype, whereas no Gb3 depositions were detected in sensory neurons derived from the female cell line, likely caused by a skewed X-chromosomal inactivation in favor of healthy GLA. Using super-resolution imaging techniques we showed that Gb3 is localized in neuronal lysosomes of male patients and in a first experiment using aSTORM microscopy we were able to visualize the neuronal membrane in great detail. To test our disease model, we treated the neurons with enzyme replacement therapy (ERT) and analyzed its effect on the cellular Gb3 load, which was reduced in the male FD-lines, compared to non-treated cells. We also identified time-dependent differences of Gb3 accumulations, of which some seemed to be resistant to ERT. We also used confocal Ca²⁺ imaging to investigate spontaneous neuronal network activity, but analysis of the dataset proofed to be difficult, nonetheless showing a high potential for further investigations. We revealed that neurons from a patient with pain are more easily excitable, compared to cells from a patient without pain and a healthy control.

We provide evidence for the potential of patient-specific iPSC to generate a neuronal in vitro disease model, showing the typical molecular FD phenotype, responding to treatment, and pointing towards underlying electrophysiological mechanisms causing different pain phenotypes. Our sensory neurons are suitable for state-of-the-art microscopy techniques, opening new possibilities for an in-depth analysis of cellular
changes, caused by pathological Gb3 accumulations. Taken together, our system can easily be used to investigate the effect of the different mutations of \textit{GLA} on a functional and a molecular level in affected neurons.
2 Zusammenfassung


3 Introduction

3.1 Fabry disease

Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by mutations in the gene encoding α-galactosidase A (GLA). Prevalence rates are ranging from 1:40,000 (Desnick et al., 2003) to 1:117,000 (Schiffmann, 2009) since large epidemiological studies are lacking. Hence, current epidemiologic data are highly dependent on the respective geographical region. A screening of male newborns in Italy, for example, showed a prevalence rate of 1:3,100 (Spada et al., 2006), whereas in the United Kingdom, a prevalence of 1:366,000 was found (MacDermot et al., 2001). Due to the X-linked inheritance, hemizygous men are earlier and more severely affected than heterozygous women (Wilcox et al., 2008). FD pathophysiology is based on the insufficient hydrolysis of α-galactose moieties which leads to the accumulation of glycosphingolipids, such as globotriaosylceramide (Gb3) in various tissues including the central and peripheral nervous system (CNS, PNS), kidneys, heart, eyes, and skin. Gb3 accumulation cause a broad range of complications, e.g. nephropathy, cardiomyopathy with arrhythmia, early-onset cerebral stroke, and FD-associated pain based on small fiber pathology (Germain, 2010). Due to the multisystem nature of FD and early involvement of the cardiovascular, renal, and cerebrovascular systems, life expectancy is reduced by 16.2 years in male and 4.6 years in female patients (Waldek et al., 2009).

3.1.1 Genetic background of FD

FD is caused by >900 different mutations with numbers rising (http://www.hgmd.cf.ac.uk). Substitutions, deletions, or insertions of nucleotides in a gene can lead to either nonsense, missense, or silent mutations, with the latter having no pathophysiological impact. Nonsense mutations may cause a premature termination codon and result in a shortened protein primary structure and thus in nonfunctional protein. Missense mutations do not lead to stop codons and therefore result in a full-length protein. Alterations in the catalytic center are particularly critical, or misfolding of the protein due to subsequent changes in the protein secondary and tertiary structure (Rodgers, 2011). This may result in degradation of the instable enzyme, or a decreased enzymatic activity (Filoni et al., 2010). This variety of mutations and effects on protein GLA likely leads to the manifestation of either a classical or nonclassical FD phenotype. Patients with the latter usually show a late-
onset and milder phenotype, whereas classical FD patients are affected early and severely (Arends et al., 2017).

3.1.2 Small fiber pathology in FD
In FD, the PNS is mainly impaired in terms of a small fiber pathology caused by a damage to the thinly-myelinated A-δ and unmyelinated C nerve fibers (Laaksonen et al., 2008). Patients develop thermal hypoesthesia with elevated warm and cold detection thresholds in functional tests such as quantitative sensory testing (Üçeyler et al., 2013). Morphologically, reduction of the intraepidermal nerve fiber density (IENFD) in skin punch biopsies may be found, while nerve conduction studies remain normal in the majority of patients pointing to an involvement of the small, rather than large nerve fibers (Scott et al., 1999). The major symptom in FD is triggerable acral burning pain, which is one of the earliest and most impairing manifestation starting in childhood and affecting men and women with FD (Burlina et al., 2011).

3.1.3 FD-associated pain
Episodic acral burning pain is a hallmark of FD starting in early childhood and affecting both genders (Üçeyler et al., 2014). Typical triggers are fever, physical activity, and heat. Pain character, distribution, and triggerability hint towards neuropathic pain, however, nociceptive components are also discussed (Üçeyler et al., 2019).

FD-associated pain is clinically diverse and can be categorized into four different phenotypes: acral evoked pain, comprising allodynia (i.e. pain triggered by usually non-painful stimuli) and hyperalgesia (i.e. increased pain upon painful stimuli), is the most common phenotype. Pain attacks are frequently reported by FD patients and are triggered by external stimuli and typically lead to acral burning pain. Avoidance or elimination of such triggers usually leads to an attenuation of pain. Fabry crisis is a rare, but extreme form of FD pain and is characterized by excruciating pain that may spread all over the body sometimes lasting for days. FD crises are often resistant to analgesic medication and patients need to be hospitalized. Chronic permanent pain is scarce in FD and mostly of mild to moderate intensity (Üçeyler et al., 2014). FD-associated pain has a great impact on health-related quality of life and the current treatment options are limited due to lack of knowledge on the underlying pathomechanisms linking Gb3 with FD pain.
3.1.4 Diagnostic criteria for FD
As a rare disease with variable phenotype, FD diagnosis is often delayed. The
diagnosis is made by determination of plasma GLA activity, which is reduced in male
patients and mostly normal in heterozygous female patients (Tsukimura et al., 2014).
Hence, genetic analysis for pathogenic mutations in the GLA gene is mandatory to
confirm diagnosis in men and women. If the diagnosis cannot be established, organ
biopsies taken from kidneys or the heart is recommended for the histological
detection of pathognomonic Gb3 accumulation (Schiffmann et al., 2017). Besides
investigation of GLA activity and genetic analysis, plasma lyso-Gb3 levels have been
established as potential prognostic marker in FD patients (Aerts et al., 2008) with
high levels indicating a classical phenotype in men and women (Tsukimura et al.,
2014).

3.1.5 FD-specific and analgesic treatment
Due to the unknown mechanisms linking Gb3 depositions with FD symptoms,
treatment is focused on reduction of these accumulations using enzyme replacement
therapy (ERT) or the recently established chaperone therapy. ERT is administered
intravenously and biweekly using recombinant agalsidase-α (Eng et al., 2001b) or
agalsidase-β (Schiffmann et al., 2001). Both drugs are similar in their
pharmacological properties and increase systemic levels of functional GLA. ERT
reduces Gb3 load in plasma, urine, skin, heart, and kidneys, whereas data about the
analgesic effect of ERT is inconclusive (Eng et al., 2001a; Schiffmann et al., 2001;
Alegra et al., 2012).

Another treatment approach is to increase endogenous enzyme activity by oral
administration of the chaperone migalastat. Migalastat is an iminosugar analogue,
which binds to the active site of GLA and stabilizes the tertiary structure of the
enzyme ensuring proper intracellular trafficking to the lysosomes (Fan et al., 1999).
Migalastat dissolves in the acidic lysosomal environment, restoring enzymatic activity
and leading to degradation of Gb3 (Germain et al., 2016). A major advantage of
migalastat is its oral intake, while its efficacy is dependent on the type of GLA
mutation and is only suitable for approximately 50% of FD patients with amenable
missense mutations (http://www.galafoldamenabilitytable.com). Hence, migalastat
can only be effective, if the mutation leads to a misfolding of GLA, but the
endogenous catalytic activity is still preserved (Giugliani et al., 2013). Long-term data
on reduction of pain is sparse and current data are inconclusive (Hughes et al., 2017).

Another promising novel treatment option is the iminosugar lucerastat applied for substrate reduction therapy, which inhibits the glucosylceramide synthase, leading to a reduction of the metabolic precursor of Gb3 and thus preventing accumulations (Guerard et al., 2018). Lucerastat is currently tested in a phase III clinical trial in which its efficacy, safety, and effect on neuropathic pain in FD is investigated (https://clinicaltrials.gov; Identifier: NCT03425539).

In the majority of cases, FD pain is not relieved by FD-specific treatment, hence, symptomatic analgesic medication is needed. Since randomized-controlled-trials are lacking, FD patients are treated following the guidelines for the treatment of neuropathic pain (Baron et al., 2010; Rolfs, 2013). Observing renal and cardiac contraindications, sodium channel blockers such as carbamazepine or phenytoin are recommended as first line analgesic treatment (Politei et al., 2016).

3.1.6 Pathophysiology of FD pain and small fiber pathology

Pathomechanistic research in FD is hindered by the lack of suitable human biomaterial that cannot be obtained easily in vivo. Although tissue collected during organ biopsies or post mortem can be used to investigate morphological changes, insight into disease mechanisms is limited. Hence, GLA deficient mouse models (GLA KO) were established to examine the effect of Gb3 depositions in vivo (Ohshima et al., 1997). GLA KO mice age-dependently develop thermal hyposensitivity and show hints for spontaneous pain behavior, resembling the human disease phenotype (Üçeyler et al., 2016). Age dependent Gb3 accumulations in GLA KO mice were detected in multiple cell types, such as dorsal root ganglia (DRG) and trigeminal neurons, or vascular smooth muscle cells, and were associated with mutations causing a classic and non-classic FD phenotype (Bangari et al., 2015). Furthermore, there is evidence for increased apoptosis of sensory neurons which may contribute to skin denervation as also seen in FD patients (Hofmann et al., 2018) and a differentiated gene expression in GLA KO DRG, pointing towards involvement of immune-related pathways in the development of the pain phenotype (Kummer et al., 2017).
However, data obtained from animal studies cannot be transferred to patients directly. To investigate pain pathophysiology, human biomaterial such as DRG neurons is needed, but can only be obtained post mortem. Hence, researchers are increasingly utilizing induced pluripotent stem cells (iPSC) to establish individual patient-specific disease models. These models offer the chance to investigate live cells obtained from the patient reflecting individual pathology. However, a specialized in vitro model to study the pathophysiology of pain in FD is still missing. Such a model system is of particular interest because FD pain is difficult to analyze in animal models and its source is still elusive. Additionally, generating a universal animal disease model is challenging because of the numerous mutations causing FD. In vitro systems, such as iPSC generated tissue may be the next step towards personalized medicine for FD to develop more specific treatment options to alleviate pain and increase patients’ quality of life.

3.2 Induced pluripotent stem cells

Pluripotency is defined as the cellular ability to differentiate into any of the three embryonic germ layers: mesoderm, ectoderm, and endoderm (Hanna et al., 2010). This potential is naturally restricted to embryonic stem cells (ESC), which are beneficial for disease modelling, but ethical concerns are a major disadvantage (Lo and Parham, 2009). In 2012, Sir John B. Gurdon and Shinya Yamanaka jointly received the Nobel Prize in Physiology or Medicine, for the discovery that mature cells can be reprogrammed to become pluripotent (https://www.nobelprize.org/).

Gurdon discovered that transplanting the nucleus of a somatic cell of Xenopus laevis into an enucleated egg of the same species results in viable tadpoles (Gurdon et al., 1958). This experiment gave first evidence that terminally differentiated cells can become pluripotent in the appropriate microenvironment. The breakthrough for modern iPSC research was achieved by Yamanaka and colleagues in 2006, who identified the genes responsible for pluripotent identity, the so called Yamanaka factors (YF) “KMOS”: Kruppel-like factor 4 (Klf4), c-Myc, octamer-binding transcription factor 4 (Oct4), sex determining region Y-box2 (Sox2), and thus have the ability to reprogram murine somatic cells to iPSC (Takahashi and Yamanaka, 2006). One year after reprogramming mouse fibroblasts, the research group around Shinya Yamanaka generated the first human iPSC from adult fibroblasts, providing the tools for today’s iPSC research (Takahashi et al., 2007).
3.2.1 Reprogramming mechanism

A hallmark of iPSC is the expression of pluripotency-associated markers, which are a product of the endogenous pluripotency network. In somatic cells, this network is silenced via epigenetic mechanisms. To achieve pluripotency, these genes have to be reactivated by remodeling the epigenome, achieved by the overexpression of YF. This leads to conformational changes of chromatin, mediated by methylation and acetylation of histones, thus rendering ESC associated genes accessible, but somatic cell specific genes inaccessible for the cellular transcription machinery (Sims et al., 2003). YF replace repressing histone modifications with activating ones on ESC genes, and vice versa for genes, which determine a somatic cell fate (Stadtfeld et al., 2008). The complete reprogramming process can be divided into two major phases (Figure 1).

![Figure 1: Reprogramming stages.](image)

In the stochastic phase, cells acquire different cell fates induced by the overexpression of YF and the underlying transcriptional changes. Cells with a reprogramming fate pass an unknown rate-limiting step and enter the deterministic phase, in which a stable endogenous pluripotency-network is established.

Briefly, in the initiation phase, gene expression of the target cells is altered to increase proliferation and metabolism. The stochastic activation and deactivation of several genes leads to multiple cell fates, such as senescence, apoptosis or reprogramming. Cells with an acquired reprogramming fate start activating endogenous pluripotency genes and enter the maturation and stabilization phase. In this phase, the epigenetic remodeling is completed, including X-chromosomal inactivation (XCI) in cells from female donors, resulting in the full reactivation of the endogenous pluripotency network (Buganim et al., 2013). Stable and mature iPSC can maintain pluripotency without exogenous delivery of transcription factors and have the ability of self-renewal.

3.2.2 Reprogramming approaches
In the early phases of iPSC research, YF were introduced into the cells via viral vectors integrating into the genome and causing their overexpression (Takahashi et al., 2007). This can lead to uncontrolled gene disruption (Stadtfeld and Hochedlinger, 2010) or formation of tumors in vivo (Okita et al., 2007), making translational use difficult. Techniques sparing the genome were established by using non-integrating virus vectors, which maintained sufficient expression of YF without integration (Fusaki et al., 2009).

A recent method is expression of the YF via transfection of the cells with mRNA (Warren et al., 2010). The mRNA is quickly degraded after induction and leads to footprint-free iPSC. Current generation reprogramming kits consist of mRNA encoding for KMOS, LIN28, and NANOG for establishing the pluripotency network. The immune evasion factors E3, K3, and B18R, necessary to inhibit the innate immune response of the cells to exogenous RNA are also delivered via mRNA. Micro RNA from the 302/367 cluster are supplemented to increase reprogramming efficiency (Poleganov et al., 2015).

3.2.3 Stem cell niches and differentiation
To maintain a sufficient pool of undifferentiated and differentiated stem cells in vivo, stem cell niches provide a specialized compartment, which regulate self-renewal, quiescence, and differentiation. These niches have a unique microenvironment, which is the result of the extracellular matrix (ECM), cell-cell interactions of stem cells with niche cells, and paracrine signaling (Spradling et al., 2008). Thus, mimicking stem cell niches in vitro is crucial for stable expansion of iPSC. Simulating paracrine
signaling can be achieved by supplementing the cultivation medium with defined growth factors (Eiselleova et al., 2009). Mouse embryonic fibroblasts, or solubilized basement membrane from extracted Engelbrecht-Holm-Swarm mouse sarcoma cells can be utilized to mimic cell-ECM interaction and paracrine signaling (Hughes et al., 2010).

During embryogenesis, neurulation leads to the formation of the CNS and PNS. To induce neural fate in iPSC, formation of the neuroectoderm is initiated by the inhibition of bone-morphogenetic protein (Lamb et al., 1993), and transforming growth factor beta mediated signaling (Sakaki-Yumoto et al., 2013). Neural crest cells, progenitors for peripheral neurons are derived from the neuroectoderm by inhibition of NOTCH (Endo et al., 2002) and MAPK1/3 (Newbern et al., 2008). Sensory fate is then established by inhibition of the glycogen synthase kinase-3 pathway (Newbern, 2015). During in vitro differentiation, these signaling pathways can be modulated by the addition of small molecules, specifically activating, or inhibiting the desired target.

3.2.4 iPSC-based disease and pain models
The ability of iPSC to differentiate into virtually any cell type makes them a powerful tool for translational research and several models have been established for diverse diseases. These range from 2D monotypic cell cultures to 3D organoids, mimicking complex organ structures in vitro usually focusing on frequent disorders such as Alzheimer’s (Tcw, 2019) or Parkinson’s disease (Li et al., 2018). Only few disease models are published concentrating on pain, such as a model for plate-based phenotypic screening for pain, using Ca\(^{2+}\) imaging (Stacey et al., 2018), or a personalized medicine approach for erythromelalgia using microelectrode arrays (Namer et al., 2018). A functional neuronal in vitro model system for FD is still missing.
3.3 Aim of this study

Due to the inaccessibility of human neuronal material *in vivo*, shortcomings of animal models, and lack of human *in vitro* disease models focusing on FD pain, we aimed at establishing an entirely human neuronal *in vitro* disease model to investigate the underlying mechanisms of FD pain. We hypothesized that we can:

1) Generate and cultivate FD-sensory neurons from skin fibroblasts via iPSC

2) Reconstitute the molecular disease phenotype in patient-specific cells

3) Adapt new techniques for analysis of FD-neurons

4) Identify yet unknown differences in cells from patients with differing pain
4 Materials and Methods

4.1 Equipment and reagents

A list of the utilized technical equipment, reagents, and specific parameters for polymerase-chain reaction (PCR) can be found in the appendices.

4.2 Patients

Three patients were chosen for biomaterial collection and cell reprogramming. Details about genotype and clinical phenotype can be found in Table 1.

Table 1: Clinical data of subjects and control person

<table>
<thead>
<tr>
<th>Line-ID</th>
<th>TK1-iPSC</th>
<th>TK8-iPSC</th>
<th>TK9-iPSC</th>
<th>Ctrl-iPSC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>Female</td>
<td>Male</td>
<td>Male</td>
<td>Male</td>
</tr>
<tr>
<td>Age at biopsy</td>
<td>25</td>
<td>28</td>
<td>27</td>
<td>62</td>
</tr>
<tr>
<td>GLA activity</td>
<td>0.22</td>
<td>0.5</td>
<td>0.04</td>
<td>N/A</td>
</tr>
<tr>
<td>Genotype</td>
<td>c.708G&gt;C (heterozygous)</td>
<td>c.1069C&gt;T (hemizygous)</td>
<td>c.568delG (hemizygous)</td>
<td>wt</td>
</tr>
<tr>
<td>Lyso-Gb3</td>
<td>11.5</td>
<td>57.7</td>
<td>241.0</td>
<td>N/A</td>
</tr>
<tr>
<td>ERT</td>
<td>None</td>
<td>Agalsidase-β</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Pain phenotype</td>
<td>Attacks</td>
<td>Attacks</td>
<td>No pain</td>
<td>N/A</td>
</tr>
<tr>
<td>Thermal sensory thresholds</td>
<td>Normal</td>
<td>Elevated</td>
<td>Normal</td>
<td>N/A</td>
</tr>
<tr>
<td>IENFD at calf (fibers/mm)</td>
<td>8.5*</td>
<td>4.9*</td>
<td>3.7*</td>
<td>N/A</td>
</tr>
</tbody>
</table>
Abbreviations: ERT = enzyme replacement therapy, Gb3 = globotriaosylceramide GLA = Alpha-1,3-fucosidase GLA = Alpha-galactosidase A, ref = reference, wt = wildtype

*Normative values at calf according to sample collection in our laboratory: 9 ± 3 fibers/mm.

Additionally, skin from the calf of a 29-year old healthy man was used for Gb3 detection in skin cryosections.

4.3 Immunocytochemistry (ICC)

For conventional ICC experiments, cells were fixed with 4% (v/v) paraformaldehyde (PFA; Electron Microscopy Sciences, Hatfield, PA, USA) in live cell imaging solution (Gibco, Waltham, MA, USA) for 20 min at room temperature (RT), washed three times with Dulbecco's phosphate buffered saline (DPBS+/+; Sigma-Aldrich, St. Louis, MS, USA) and blocked with 5% (v/v) fetal calf serum (FCS; Merck, Darmstadt, Germany)/DPBS+/+ for 30 min at RT. For super-resolution microscopy, cells were fixed for 1 h at RT with 5% (v/v) glyoxal (pH=5), quenched with 100 mM glycine for 30 min and blocked as described above (both Sigma-Aldrich, St. Louis, MS, USA). For intracellular targets, 0.1% (w/v) saponin (Sigma-Aldrich, St. Louis, MS, USA) was added to the blocking buffer for membrane permeabilization. Primary antibodies were diluted (see Table 8) in the blocking solution and cells were incubated for 16 h at 4°C. After washing three times with DPBS+/+, the corresponding secondary antibody (see Table 9), diluted in DPBS+/+ was added to the cells and incubated for 30 min at RT. Shiga toxin 1, B subunit (STxB)::555 or STxB::647, detecting Gb3 and globotetrahexosylceramide (Gb4), kindly provided by the Department of Biotechnology and Biophysics, Würzburg (Prof. Markus Sauer), was added to the secondary antibody, where applicable. Cells were incubated with 700 nM 4',6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich, St. Louis, MS, USA) for 5 min, washed with DPBS+/+ and mounted with Aqua-Poly/Mount (Polysciences, Warrington, PA, USA), or ProLong™ Glass Antifade (Thermo Fisher Scientific, Waltham, MA, USA) for super-resolution imaging.

4.3.1 Labeling of extracellular targets

Live cells were incubated on ice for 20 minutes with 5 µM double knot toxin-His₆ (DkTx; Mybiosource.com, San Diego, CA, USA), washed three times with DPBS+/+, followed by the previously described routine ICC protocols for multiplex labeling. An
Anti-His::647 antibody (GenScript Biotech, Nanjing, China) was used for detection of DkTx.

4.3.2 dSTORM imaging
One week before analysis, 5 week old neurons were replated on 8-well cell culture glass chamber slides (Sarstedt, Nürnbrecht, Germany) and cultivated for 1 week, as usual. Cells were incubated live with 5 µg/ml Cholera toxin B subunit (CTxB; Sigma-Aldrich, St. Louis, MS, USA) conjugated with Alexa Fluor 647 (Thermo Fisher Scientific, Waltham, MA, USA) for 15 min, washed with PBS and fixed with 2% PFA/0.2% glutaraldehyde (Sigma-Aldrich, St. Louis, MS, USA). 100 mM cysteamine was used as switching buffer (Sigma-Aldrich, St. Louis, MS, USA). Images were reconstructed using the ThunderSTORM plugin for ImageJ (Ovesny et al., 2014).

4.4 Immunohistochemistry
Skin tissue from skin punch biopsies were fixed, embedded in Tissue-Tek® O.C.T.™ (Sakura, Tokyo, Japan), and cut in 40-µm sections using a cryostat (Leica Microsystems, Wetzlar, Germany). Sections were blocked for 30 min at RT with 10% (w/v) bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MS, USA)/DPBS−/− and STxB::555, diluted in 1% (w/v) BSA/DPBS−/− + 0.1% (w/v) saponin and incubated for 16 h at 4°C. Sections were washed and mounted with VECTASHIELD® antifade mounting medium with DAPI (Vector Labs, Burlingame, CA, USA).

4.5 Imaging setups
Different microscope setups were used for biomaterial analysis.

4.5.1 Conventional epifluorescence
The following systems were used for conventional epifluorescence imaging: Leica DMi8 microscope equipped with a DFC3000G CCD camera, EL6000 light source, and Leica Application Suite X (abbreviated as DMi8 in further sections; all: Leica Microsystems, Wetzlar, Germany). Zeiss Axiophot2, excitation by HXP 120C (Zeiss, Oberkochen, Germany) with a SPOT INSIGHT™ camera and SPOT Software (abbreviated as Axiophot in further sections; both: Diagnostic Instruments, Sterling Heights, MI, USA). Zeiss Imager M.2 with an Apotome 2 device for structured illumination, Colibri 7 LED as light source, an Axiocam 506 mono CCD camera, and Zeiss ZEN Blue edition as software (abbreviated as Apotome in further sections; all: Zeiss, Oberkochen, Germany).
4.5.2 Phase contrast imaging
Images of *in vitro* cultures were acquired with a Leica DMI IL LED inverted microscope, with a DMC2900 CCD camera and Leica Application Suite as software (abbreviated as DMI IL LED in further sections; all: Leica Microsystems, Wetzlar, Germany).

4.5.3 Super-resolution and confocal imaging
Structured illumination microscopy (SIM) images were acquired using an Elyra S.1 microscope (Zeiss, Oberkochen; Germany) with a PCO Edge 5.5 cMOS camera (PCO, Kelheim, Germany) and 405 nm, 488 nm, 561 nm, and 642 nm laser lines. Abbreviated as SIM in following sections.

Direct stochastic optical reconstruction microscopy (dSTORM) experiments were performed with a custom built setup, based on an Axio Observer.Z1 body (Zeiss, Oberkochen, Germany) with two Andor EMCCD iXon Ultra DU-897 cameras (Oxford Instruments, Abingdon, UK) and 405 nm, 488 nm, 532 nm, and 640 nm laser lines. Abbreviated as dSTORM in following sections.

An LSM700 microscope, with two photomultipliers and 488 nm, 555 nm, and 639 nm laser lines (all: Zeiss, Oberkochen, Germany) was used for confocal laser scanning microscopy (CLSM). Abbreviated CLSM in further sections. SIM, CLSM, and dSTORM images were acquired at the Department of Biotechnology and Biophysics, Würzburg in collaboration with Jan Schlegel, M.Sc.

4.6 Skin punch biopsy and human dermal fibroblast (HDF) cultivation
A six-mm skin punch biopsy was obtained by the treating physician from the locally anesthetized calf following a standard procedure (Üçeyler et al., 2010). Dermis and epidermis were mechanically separated, the dermal part was cut into small pieces and placed in a tissue culture (TC) flask. Fibroblast cultivation medium (DMEM/F12, 120 U/ml penicillin, 100 µg/ml streptomycin [all: Gibco, Waltham, MA, USA], 10% FCS) was added and cells were cultivated at 37°C in 5% CO₂ (v/v). Once HDF grew out of the tissue pieces and were 60-80% confluent, cells were passaged using TrypLE™ Express (Gibco, Waltham, MA, USA). Medium was changed twice a week.
4.7 Reprogramming of HDF to iPSC and clonal expansion

For reprogramming, two different commercially available kits were used. TK1-iPSC were generated using StemMACS™ mRNA reprogramming kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to manufacturer’s protocol, with the following minor modifications: cells were reprogrammed in a 12-well format instead of the 6-well format. Volumes of reagents were adjusted accordingly (Klein, 2016). TK8 and TK9 iPSC were generated using the StemRNA 3rd Gen reprogramming kit (Reprocell, Kanagawa, Japan), as recommended by the manufacturer.

Anti-TRA-1-60 live cell staining antibody was used (1:100; Miltenyi Biotec, Bergisch Gladbach, Germany) to identify putative iPSC colonies after reprogramming. Colonies were manually picked and initially cultivated in a 24-well plate (TK1 clones), or 12-well plate (TK8, TK9), respectively and expanded to a 6-well cultivation format.

4.8 Cultivation of iPSC

iPSC were cultivated on TC plates, coated with hESC qualified Matrigel® (ES-Mg; Corning, Corning, NY, USA). For coating, 250 µl ES-Mg was diluted in 25 ml ice cold DMEM/F12 medium and 111 µl/cm² was added to the wells and incubated for at least 16 h at 4°C. Before seeding, excessive ECM was aspirated.

StemMACS™ iPS-Brew (Miltenyi Biotec, Bergisch Gladbach, Germany), supplemented with 120 U/ml penicillin and 100 µg/ml streptomycin, called "iPSC-medium" in the following sections, was used as cultivation medium. Once cells reached 80% confluency, medium was aspirated, incubated for 8 minutes with 2 mM ethylenediaminetetraacetic acid/DPBS without calcium and magnesium- (EDTA/DPBS-; Thermo Fisher Scientific, Waltham, MA, USA), and centrifuged (300 rcf, 3 min, RT). Cells were seeded with the desired density in ES-Mg coated wells. 10 µM Y-27632 (ROCKi; Miltenyi Biotec, Bergisch Gladbach, Germany) was added to the iPSC-medium for the first 24 h. Cells were kept at 37°C in 5% CO₂ (v/v) and medium was changed daily. Cells from early passages were cryoconserved in KnockOut™ serum replacement (KO-SR; Thermo Fisher, Waltham, MA, USA), containing 10% dimethyl sulfoxide (DMSO; Sigma-Aldrich, St. Louis, MS, USA) and 10 µM ROCKi, in the gas phase of liquid N₂.
4.9 Characterization of putative iPSC

To ensure high quality iPSC lines, cells were analyzed for various parameters, such as morphology, expression of stemness genes, the potential to differentiate into cell types of the meso-, endo-, and ectodermal germ layers, and genetic integrity.

4.9.1 Trilineage differentiation

For differentiation of iPSC into all three germ layers, the commercial StemMACS™ Trilineage Differentiation Kit, human” (Miltenyi Biotec, Bergisch Gladbach, Germany) was used following the manufacturers’ recommendations. Cells were analyzed via immunocytochemistry (ICC, see section 4.3) with mesodermal (smooth muscle protein 22 alpha, [SM22A]), endodermal (forkhead box protein A2, [FOXA2]), and ectodermal (sex determining region y-box 2 [SOX2] and paired box protein 6 [PAX6]) markers.

4.9.2 Flow cytometry

Quantitative analysis of the expression of the pluripotency-associated surface markers stage-specific embryonic antigen-4 (SSEA-4) and tumor resistance antigen 1-60 (TRA-1-60) was performed using flow cytometry. 3x10^6 iPSC were harvested as single cells using accutase (Gibco, Waltham, MA, USA), washed with DPBS⁻/⁻ and kept on ice for the remaining steps. 1x10^6 cells were used as the unstained control. The remaining cells were incubated for 15 min at 4°C with Viobility™ 405/452 Fixable Dye (1:1000; Miltenyi Biotec, Bergisch Gladbach, Germany) for live/dead discrimination. Cells were blocked with 5% (v/v) FCS/DPBS⁻/⁻ by centrifugation (300 rcf, 3 min, 4°C) and 1x10^6 cells were incubated with TRA-1-60 and SSEA4 antibodies, labelled with allophycocyanin (APC) or phycoerythrin (PE), respectively (both 1:11; Miltenyi Biotec, Bergisch Gladbach, Germany) for 15 min at 4°C. The remaining cells were incubated similarly with matching isotype control antibodies (1:50; REA Control (S)-APC and REA Control (S)-PE; Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were washed with DPBS⁻/⁻ by three centrifugation steps (300 rcf, 3 min, 4°C). Cells were resuspended in DPBS⁻/⁻ and analyzed with a BD FACSCanto™ II or BD LSR II flow cytometer with FACSDiva™ software (all BD Bioscience, East Rutherford, UK).

For data acquisition, the background signal was evaluated using the unstained and the isotype control and gated accordingly. Only living single cells were included,
using the live/dead discrimination and forward/side scatter. Final analysis was performed using FlowJo v10 software (FlowJo, Ashland, OR, USA).

4.9.3 Sanger sequencing

To verify the presence of the disease associated mutation, genomic DNA (gDNA) from 3x10^6 iPSC was purified using the DNeasy Blood & Tissue kit (Qiagen, Venlo, Netherlands), as recommended by the manufacturer. PCR was set up as stated in with the corresponding primers (see Table 7; Sigma Aldrich, St. Louis, MS, USA) for the mutation using One Taq® Hot Start 2X Master Mix with standard buffer, as recommended by the manufacturer (New England Biolabs, Ipswich, MS, USA). PCR products were sent to Eurofins Scientific (Luxembourg, Luxembourg) for purification and Sanger sequencing. Data was analyzed using DNA Baser v4 software (Heracle BioSoft, Pitesti, Romania).

4.9.4 Mycoplasma detection

iPSC were monitored for mycoplasma contamination using a PCR-based assay. Conditioned medium was collected, centrifuged (5000 rcf, 5 min, RT), supernatant aspirated, resuspended in 100 µl lysis buffer (see Table 5), and incubated for 5 min at 90°C. 100 µl of 40 mM TrisHCl (Sigma Aldrich, St. Louis, MS; USA) was added to neutralize the lysis buffer and the sample was centrifuged (5000 rcf, 1 min, RT). Isolated DNA was amplified using PCR with mycoplasma genus specific primers (see Table 7) and analyzed using agarose gel electrophoresis. The positive control consisted of purified DNA from a contaminated culture.

4.10 TK1-iPSC GLA transcriptomics and XCI

To investigate the presence of the mutated GLA on a transcriptional level, total RNA from TK1-iPSC was extracted and translated into cDNA, as described (see section 4.13). The mutation site was amplified using PCR (see Table 7) and sequenced, as described (see section 4.9.3.)

XCI was investigated at the Institute of Human Genetics, University of Würzburg (Prof. Eva Klopocki) using a methylation sensitive HhaI enzyme digestion assay (Promega, Madison, WI, USA).
4.11 Differentiation of iPSC into sensory neurons

A previously published protocol was modified and adapted to generate iPSC derived sensory neurons (Eberhardt et al., 2015). For differentiation experiments, TC plates were coated using Growth Factor Reduced Matrigel® (bMg; Corning, Corning, NY, USA), as previously described (see section 4.8), but diluting 500 µl bMg in 25 ml medium.

Medium was changed daily until day 10 of the differentiation. On day -2 of the differentiation, iPSC were harvested when 80-90% confluence was reached, by incubation of the cells with 600 µl accutase for 8 min at 37°C. The single cell suspension was centrifuged (300 rcf, 3 min, RT) resuspended in iPSC cultivation medium with 10 µM ROCKi, and 125,000 cells/cm² were seeded and cultivated for 2 d, as usual. On day 0, medium was switched to differentiation (KSR) medium (KO DMEM/F12, 15% KO-SR, 2 mM GlutaMAX™, 100 µM β-mercaptoethanol, 1% minimum essential medium non-essential amino acids, 100 U/ml penicillin, 100 µg/ml streptomycin [all Thermo Fisher Scientific, Waltham, MA, USA]) supplemented with 2i (100 nM LDN193189 [Stemcell Technologies, Vancouver, Canada], 10 µM SB431542 [Miltenyi Biotec, Bergisch Gladbach, Germany]) for 2 d, followed by 2 d with KSR, supplemented with 5i (100 nM LDN193189, 10 µM SB431542, 10 µM SU5402, 10 µM DAPT [both Sigma-Aldrich, St. Louis, MS, USA], and 3 µM CHIR99021 [Axon Medchem, Groningen, The Netherlands]). Beginning from day 4, N2 medium (DMEM/F12 + GlutaMAX™, B-27 Plus, N-2 Supplement [all: Thermo Fisher Scientific, Waltham, MA, USA], 100 U/ml Penicillin, 100 µg/ml streptomycin) with 5i was added to KSR-5i medium in 25% increments, every other day, until day 9. On day 10, cells were detached using incubation at 37°C with TrypLE™ Express and centrifuged (300 rcf, 3 min, RT). The cell pellet was resuspended in maturation medium (N2 medium, supplemented with 200 ng/ml ascorbic acid [Sigma Aldrich, St. Louis, MS, USA], 20 ng/ml beta-nerve growth factor [βNGF], 20 ng/ml brain-derived neurotrophic factor [BDNF] and 20 ng/ml glial cell line-derived neurotrophic factor [GDNF; all from Peprotech, Rocky Hill, NJ, USA]), spiked with 10 µM floxuridine (FdU, Santa Cruz Biotechnology, Dallas, TX, USA), and seeded either onto bMg coated high precision cover glass (Paul Marienfeld, Lauda Königshofen, Germany) or TC plates for subsequent analysis. Additionally to FdU, 1 µg/ml Mitomycin C (Stemcell Technologies, Vancouver, Canada) and CultureOne Supplement (Thermo
Fisher Scientific, Waltham, MA, USA) were tested as cytostatics. Half of the medium was changed at least once a week, depending on media consumption, as indicated by the phenol red pH indicator, present in the medium. Neurons were cultivated for at least 6 weeks (“mature neurons”) before analysis, unless otherwise stated. Replating of mature neurons was performed as described for day 10, including FdU treatment, but using conditioned medium instead of fresh maturation medium. One week old neurons are defined as “young” in the following sections.

4.12 Functional tests of iPSC-derived sensory neurons

Cultivated neurons were investigated for their response to ERT and the pro-inflammatory cytokine tumor necrosis factor-α (TNF) as potential pain trigger in vivo (Üçeyler et al., 2019).

4.12.1 Incubation with agalsidase-β

Neurons were incubated with 1.32 µg/ml agalsidase-β (Sanofi, Paris, France) to investigate the pharmacological response as follows: conditioned medium was collected from neurons, mixed 1:1 with fresh maturation medium, containing 2.64 µg/ml agalsidase-β and added to the neurons for 24 h. Cells were directly analyzed afterwards. For the untreated cells, medium was changed as described, lacking agalsidase-β.

4.12.2 Incubation with TNF

To mimic an inflammatory environment as one of the major pain triggers in FD patients, mature neurons were challenged with TNF for 72 h (Üçeyler et al., 2019). Briefly, TNF was reconstituted in H2O and diluted in 6% (w/v) trehalose (both Sigma-Aldrich, St. Louis, MS, USA). A mixture, containing 50% conditioned and 50% fresh maturation medium was used to dilute the compound to a final concentration of 1000 U/ml and neurons were incubated for 72 h at 37°C and 5% CO2 (v/v). Neurons were incubated with 6% trehalose lacking TNF as the negative control. Cells were fixed, processed for ICC (see section 4.3) and Gb3 accumulations were quantified (see section 4.12.3).

4.12.3 Quantification of neuronal Gb3 accumulations

Neurons were fixed and stained, as described (see section 4.3) with an antibody against class III β-tubulin (TUJ1; Abcam, Cambridge, UK) and STxB::555 (Sigma-Aldrich, St. Louis, MS, USA). Whole coverslips were scanned using a DMI8 inverted
microscope, with a 20X objective (Leica Microsystems, Wetzlar, Germany, Figure 2 A). 150 TUJ1+ cells were counted per sample using the cell counter plugin for ImageJ (National Institute of Health, New York City, NY, USA). STxB positive accumulations were determined in the same manner and diversified into four subgroups (see Table 2). A person not otherwise involved in the project and blinded as to sample allocation (Bettina Vignolo, B.Sc.) analyzed images.

Table 2: Diversification of STxB accumulations

<table>
<thead>
<tr>
<th>Accumulation subgroup</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>No signal</td>
<td>Complete absence of STxB accumulations (Figure 2 B)</td>
</tr>
<tr>
<td>Focal</td>
<td>Small, highly intense, confined accumulations (Figure 2 C)</td>
</tr>
<tr>
<td>Scattered</td>
<td>Many accumulations spread out in the whole soma (Figure 2 D)</td>
</tr>
<tr>
<td>Mixed</td>
<td>Cells with scattered and focal accumulations (Figure 2 E)</td>
</tr>
<tr>
<td>Total</td>
<td>Sum of mixed, scattered, and focal accumulations</td>
</tr>
</tbody>
</table>
Figure 2: **Classification of Gb3 accumulations.** (A) Exemplary image for quantification. (B) No accumulations, (C) focal (yellow arrow), (D) scattered (white arrow), and (E) cells with mixed accumulations. Scale bars: 100 µm (A); 25 µm (B-D). All acquired with DMi8.
Abbreviations: DAPI = 4′,6-diamidino-2-phenylindole; TUJ1 = neuron-specific class III β-tubulin; STxB = Shiga Toxin1, B subunit

4.12.4 Confocal Ca\(^{2+}\) imaging

One week before analysis, 5 week old neurons were replated on 8-well cell culture glass chamber slides (Sarstedt, Nürenbrecht, Germany) and cultivated for 1 week, as usual. Cells were loaded with 2 µM Fluo-8 AM (Abcam, Cambridge, UK) for 1 h at 37°C, washed with conditioned medium and acquired with the CLSM setup in a live-cell acquisition chamber (Tokai Hit, Shizuoka, Japan) under physiological conditions (5% [v/v] CO\(_2\), 37°C medium, 39°C heated lid). Data was collected with a sampling rate of 0.25 Hz for a total of 8 minutes. Data was analyzed using the open source NA\(^{3}\) software (Prada et al., 2018).

4.12.5 Patch clamp analysis

Data acquisition and analysis for patch clamp experiments were performed by Dr. Lukas Hofmann in our laboratory.

Mature neurons were transferred into the recording chamber, containing bath solution (see Table 5) at RT. Borosilicate glass capillaries (Kimble Chase Life Science and Research Products, Meiningen, Germany) were pulled and heat-polished to patch pipettes with an input resistance of 1 – 4 MΩ containing pipette solution (see Table 5). Whole cell current clamp was recorded with an EPC10 patch clamp amplifier with a sampling rate of 20 kHz and data was acquired and analyzed using Patch Master software (both: HEKA, Ludwigshafen, Germany). To quantify action potentials (AP), neurons were stimulated with a single current pulse for 10 ms. Action potential threshold difference (V\(_{\text{ThresholdDiff}}\)) was calculated by subtracting the resting membrane potential (V\(_{\text{Mem}}\)) from the threshold potential (V\(_{\text{Threshold}}\)) to quantify the degree of neuronal excitability.

4.13 Quantitative real-time PCR (qRT-PCR) experiments

Total RNA was extracted from neurons using the miRNeasy Micro Kit and from iPSC using the miRNeasy Mini Kit (both Qiagen, Hilden, Germany) and 250 ng RNA was reverse transcribed into cDNA applying TaqMan reverse transcription reagents (Thermo Fisher Scientific, Waltham, MA, USA), as recommended by the manufacturers. 5 ng cDNA was used for gene expression studies using TaqMan probes (Table 6) with 18S ribosomal RNA as endogenous control (all: Thermo Fisher Scientific, Waltham, MA, USA).
Data was acquired with a QuantStudio™ 3 Real-Time PCR system with technical triplicates and analyzed using QuantStudio™ Design and Analysis software (both Thermo Fisher Scientific, Waltham, MA, USA) applying the ΔC_T method, normalizing expression of markers in iPSC to 1 and using the $1/\Delta C_T$ value for visualization.

4.14 Statistical analysis

IBM SPSS Statistics Version 26 software (IBM, Armonk, NY, USA) was used for statistical analysis. Data was analyzed using the non-parametric Mann-Whitney U test, after the Kolmogorov-Smirnov test showed a non-normal distribution. Results were visualized using GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA) as interleaved bar (Figure 16, Figure 22) and interleaved scattered plots (Figure 18, Figure 19, Figure 20, Figure 21). Data points represent mean ± standard deviation, as appropriate.
5 Results
5.1 Generation and characterization of one female FD-iPSC line

First, we characterized our female FD-iPSC line. After initial reprogramming of HDF (Figure 3 A) and expansion of a single putative iPSC clone, cells showed ESC-like morphology with small, compact cells with a high nucleus:cytoplasm ratio with defined colony borders (Figure 3 B). Genetic analysis showed no chromosomal aberration as shown by G-banding (Figure 3 C). Expression of the pluripotency markers TRA-1-60, OCT4 and SSEA4 was confirmed by ICC (Figure 3 D).

Quantitative analysis of TRA-1-60 and SSEA4 showed a coexpression on >94% of live single cells, proofing a homogenous expression (Figure 3 E). The disease associated mutation was present in TK1-iPSC, but not in Ctrl-iPSC (Figure 3 F).

Directed differentiation into meso-, endo-, and ectodermal lineage resulted in cells expressing the germ-layer specific markers SOX2/PAX6 (ectoderm), FOXA2 (endoderm), and SM22A (mesoderm), confirming true pluripotency. No mycoplasma was detected (supplementary Figure 31 A)
**Figure 3: Characterization of a female FD-iPSC line.** (A) HDF showed (B) typical ESC-like morphology after reprogramming. (C) No chromosomal aberrations were found and (D) expression of stemness marker was confirmed by ICC qualitatively and (E) quantitatively. (F) The disease associated mutation c.708G>C was present in gDNA. (G) iPSC could be differentiated into cells of all three germ-layers, as shown by immunoreactions against specific markers. Scale bars: 50 µm.; Acquired with DMI IL LED (A, B) and Apotome (D, G).

Abbreviations: APC = allophycocyanin; Ctrl = control; DAPI = 4',6-diamidino-2-phenylindole; ESC = embryonic stem cell; FOXA2 = forkhead box protein A2; HDF = human dermal fibroblasts; iPSC = induced pluripotent stem cells; OCT4 = octamer-binding transcription factor 4; PAX6 = paired box 6, PE = phycoerythrin; SM22A = smooth muscle protein 22-alpha; SOX2 = sex determining region Y box 2; SSEA4 = stage specific embryonic antigen 4; TRA-1-60 = tumor resistance antigen 1-60

5.2 Gb3 accumulation in TK1-iPSC and neurons

Accumulations were detected with STxB::555 in early (<p5) iPSC (Figure 4 A), but not in late (>p5) iPSC (Figure 4 B). Furthermore, no difference in the STxB signal was observed between TK1 and control neurons, labelled with peripherin (PRPH; Figure 4 C, D)

![Early iPSC](image1.png) ![Late iPSC](image2.png)  
*iPSC*  
**TK1**  
**Ctrl**

**Figure 4: Gb3 accumulations in FD-cells from female subject.** (A) StxB-positive profiles could be detected in early (p<5) iPSC, but (B) were missing in late (p>5) iPSC. No accumulations were detected in (C) TK1 iPSC-derived neurons, similar to (D) control iPSC-derived neurons. Scale bars: 25 µm. All acquired with CLSM.
5.3 gDNA/cDNA analysis for TK1-iPSC

Analysis of GLA gDNA of late iPSC showed the presence of the disease-associated mutation c.708G>C, but its absence in cDNA, generated from mRNA specific for the mutation site (Figure 5 A). Further investigation of XCI via methylation-sensitive HhaI digestion showed a skewed inactivation towards one genotype in late iPSC, with a ratio of 100:0 (Figure 5 B).

**Figure 5: Genetic and transcriptomic analysis of TK1-FD-iPSC.** (A) Presence of c.708G>C in the gDNA, but not in cDNA. (B) Full inactivation of one X-chromosome, as shown by methylation sensitive HhaI digestion.
5.4 **Gb3 accumulations in male skin samples**

Gb3 depositions in skin cryosections were analyzed for TK8, TK9, and a healthy control subject.

As shown in Figure 6, STxB\(^+\) profiles are localized in the dermal part of TK8 (Figure 6 A) and TK9 (Figure 6 B), whereas no signal was detected in the healthy control (Figure 6 C). No sample showed accumulations in the epidermal part (Figure 6 A’ – C’).

**Figure 6: Gb3 accumulations in skin cryosections.** Gb3 accumulations are located in the dermal layer of (A) TK8 and (B) TK9. (C) No depositions were detected in the healthy control. (A’ – C’) Higher magnification of the epidermal – dermal junction (yellow line). Scale bars: 50 µm. All acquired with Apotome. Yellow dotted line marks dermal-epidermal border.

Abbreviations: DAPI = 4′,6-diamidino-2-phenylindole; STxB = Shiga Toxin1, B subunit
5.5 Generation and characterization of four male FD-PSC lines

5.5.1 mRNA reprogramming of TK8

During reprogramming, HDF underwent substantial morphological changes from spindle-shaped cells before transfection (Figure 7 A) to compact cells, forming small colonies on the last day of transfection (Figure 7 B). Prolonged cultivation for 4 additional days resulted in small demarcated colonies (white arrows), which grew in size (Figure 7 C) and density over time until ready for picking and subcultivation (white arrow), 10 days after the last transfection (Figure 7 D).

Figure 7: Morphological changes during reprogramming. (A) HDF before transfection, exhibiting typical spindle-shaped cell bodies. (B) After 4 transfections, cells started forming colonies of small and roundish cells, which (C) grew bigger 8 days and (D) became more dense, 10 days after the initial delivery of YF. White arrows indicate emerging putative iPSC colonies. Scale bars: 200 µm. All acquired with DMI IL LED.
Abbreviations: HDF = human dermal fibroblast; iPSC = induced pluripotent stem cells; YF = Yamanka factors

5.5.2 Full characterization of TK8 and TK9 iPSC lines
From each patient TK8 and TK9, two individual clones were chosen for experiments and fully characterized. In this section, data of one clone of each patient is presented; data of the second clone is detailed in the supplementary (see section 8.8):
Figure 8: Characterization of TK8 clone 6. (A) HDF were reprogrammed to (B) iPSC with ESC-like morphology. (C) No chromosomal aberrations were found and (D) robust expression of the pluripotency markers was confirmed. (E) > 98% of live, single cells coexpressed TRA-1-60 and SSEA4, with (F) the retained c.1069C>T mutation. (G) Directed differentiation of cells into all three germ-layers was successful. Scale bars: 200 µm (A, B); 50 µm (D, G). Acquired with DMI IL LED (A, B) and Apotome (D, G).

Abbreviations: Ctrl = control; DAPI = 4',6-diamidino-2-phenylindole; ESC = embryonic stem cell; FOXA2 = forkhead box protein A2; HDF = human dermal fibroblasts; iPSC = induced pluripotent stem cells; OCT4 = octamer-binding transcription factor 4; PAX6 = paired box 6, SM22A = smooth muscle protein 22-alpha; SOX2 = sex determining region Y box 2; SSEA4 = stage specific embryonic antigen 4; TRA-1-60 = tumor resistance antigen 1-60

HDF (Figure 8 A; Figure 9 A) were reprogrammed to putative iPSC showing ESC-like morphology (Figure 8 B; Figure 9 B), and no numerical or relevant chromosomal abnormalities (Figure 8 C; Figure 9 C). The expression of TRA-1-60, OCT4 and SSEA4 was easily detected by ICC (Figure 8 D; Figure 9 D). Quantitative analysis of SSEA4 and TRA-1-60 showed a SSEA4+/TRA-1-60+ cell population of 98.7 %, and 96.9 %, respectively (Figure 8 E; Figure 9 E). The disease-associated mutation c.1069C>T for TK8 and c.568delG for TK9 was present in iPSC gDNA (Figure 8 F; Figure 9 F). iPSC were differentiated into cells of the ecto-, endo-, and mesoderm as shown by ICC against the germ-layer specific markers PAX6/SOX2 (ectoderm), FOXA2 (endoderm), and SM22A (mesoderm; Figure 8 G; Figure 9 G). No mycoplasma was detected (supplementary Figure 31 A)
Figure 9: Characterization of TK9 clone 4. Transfection of (A) HDF with YF, resulted in (B), cells, morphological resembling ESC. (C) Chromosomal aberrations were non-existent and (D) expression of
key pluripotency markers was confirmed, with (E) >96% of analyzed cells being TRA-1-60/SSEA double positive. (F) The disease-associated c.568delG mutation was confirmed in iPSC as well as (G) expression of germ-layer markers after directed differentiation. Scale bars: 200 µm (A, B); 50 µm (D, G). Acquired with DMI IL LED (A, B) and Apotome (D, G).

Abbreviations: Ctrl = control; DAPI = 4′,6-diamidino-2-phenylindole; ESC = embryonic stem cell; FOXA2 = forkhead box protein A2; HDF = human dermal fibroblasts; iPSC = induced pluripotent stem cells; OCT4 = octamer-binding transcription factor 4; PAX6 = paired box 6, SM22A = smooth muscle protein 22-alpha; SOX2 = sex determining region Y box 2; SSEA4 = stage specific embryonic antigen 4; TRA-1-60 = tumor resistance antigen 1-60

5.6 Gb3 accumulations in male FD-iPSC lines

Clones from TK8 and TK9 were analyzed for Gb3 depositions using STxB. Data of one clone of each cell line is presented.

![Figure 10: Gb3 accumulations in male FD-iPSC.](image)

(A) TK8 and (B) TK9 iPSC showed strong intracellular STxB-signal, whereas (C) no signal was detected in control iPSC. Scale bars: 50 µm. All acquired with Apotome.

Abbreviations: Ctrl = control, DAPI = 4′,6-Diamidin-2-phenylindol; iPSC = induced pluripotent stem cells; STxB = Shiga toxin1, B subunit

Both FD-iPSC lines showed numerous STxB positive accumulations (Figure 10 A, B) in contrast to control cells, where no depositions were detected (Figure 10 C).
5.7 Sensory neuron differentiation of iPSC

The differentiation protocol was established using the TK1 cell line and applied to the control, TK8, and TK9 cell lines. Data shown in this section is from the control line, if not otherwise stated.

5.7.1 Time course of the differentiation

iPSC were seeded with such a high density that an overconfluent monolayer was formed 2 days after the start of differentiation (Figure 11 A). Ten days after neuronal initiation, ganglia-like structures emerged (black arrow) with underlying non-neuronal, highly proliferative cells (white arrow; Figure 11 B). Cells were split, neurons regrouped into clusters, from which feeder-layer cells grew out (white arrow; Figure 11 C). After 6 weeks of maturation the feeder-layer cell number was greatly reduced with neurons (black arrow) adhering on top of the remaining cells (white arrow; Figure 11 D).

Figure 11: Neuronal differentiation. (A) Overconfluent cells with iPSC morphology on day 2, differentiated into (B) ganglia-like structure with neuronal processes (black arrow) after 10 days of differentiation, together with non-neuronal cells (white arrow). (C) Outgrowth of unspecified proliferative
cells from clusters 1 day after the neuronal split (white arrow). (D) Dying back of feeder layer cells with neurons attaching on top of the remaining cells (white arrow), showing nociceptive morphology (black arrow). Scale bars: 200 µm. All acquired with DMI IL LED.

Abbreviations: iPSC = induced pluripotent stem cells

5.7.2 Assessment of cytostatic compounds

To reduce non-neuronal cells, three different inhibitors were tested: FdU, CultureOne, and Mitomycin C.

Treatment with FdU resulted in a reduction of feeder layer cells, whereas neuronal structures seemed to be unaffected (Figure 12 A). The CultureOne treatment resulted in massive cell death of all cell types (Figure 12 B). Mitomycin C effectively reduced non-neuronal populations, but seemed to stress neurites (Figure 12 C). Images were acquired 1 week after initial treatment.

<table>
<thead>
<tr>
<th>FdU</th>
<th>CultureOne</th>
<th>Mitomycin C</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>B</td>
<td>C</td>
</tr>
</tbody>
</table>

Figure 12: Comparison of cytostatics. (A) No neurotoxicity was caused by FdU, in contrast to (B) massive neuronal death with CultureOne. (C) Mitomycin C killed feeder-layer cells, but had a negative effect on neurons. Scale bars: 200 µm. All acquired with DMI IL LED.

Abbreviations: FdU = floxuridine

5.7.3 Marker expression during differentiation phase

To investigate expression of key markers, cells were fixed and analyzed every 2 days, during the first 10 days of differentiation.

The pluripotency marker OCT4 was highly expressed on day 2 and declined rapidly after 4 days of differentiation until no expression was detectable from day 6 onward. No expression of the sensory marker BRN3A was found during the first 4 days, but was abundant from day 6 on (Figure 13 A – A'). PAX6, a key marker for neural crest fate was expressed starting from day 2, seemed to be most plentiful on day 6 and decreased afterwards. SOX10, a marker for neural progenitor and glial cells, had overall low expression starting from day 6, and was slightly increased on day 10
(Figure 13 B – B’’’). The pan-neuronal marker TUJ1 and peripheral neuronal marker PRPH were absent on day 2 and showed increased expression starting from at least day 6. The amount of PRPH+ cells increased over time. No data was obtained for this immunoreaction on day 4 and no DAPI counterstaining was done for day 10 (Figure 13 C – C’’’).

Day 2

Day 4

No data obtained for:
PRPH
TUJ1

Day 6

Continued on next page.
**Figure 13: Key marker expression during neuronal differentiation.** (A – A’’) The expression of OCT4 declined over time, whereas BRN3A expression increased during the differentiation. (B – B’’) PAX6 expression started on day 2 and was upregulated during the differentiation. SOX10 was detectable starting from day 6 onwards. (C – C’’) TUJ1 and PRPH were absent during the first 6 days, but were highly upregulated from then on. Scale bars: 100 µm. All acquired with Axiophot.

Abbreviations: BRN3A = POU class4 homebox 1; DAPI = 4′,6-diamidino-2-phenylindole; OCT4 = octamer-binding transcription factor 4; PAX6 = paired box 6; PRPH = peripherin; SOX10 = sex determining region Y-box 10; TUJ1 = neuron-specific class III β-tubulin

5.7.4 Marker expression on mature neurons - ICC

Expression of key markers for the sensory fate of neurons was determined during establishment of the differentiation protocol on the control-iPSC line.

Mature control neurons expressed the pan-neuronal marker TUJ1 and the peripheral neuronal marker PRPH (Figure 14 A). Voltage gated sodium channel 1.8 (Na\(_{v}1.8\)) was highly expressed on neurons (Figure 14 B), whereas transient-receptor potential cation channel subfamily V member 1 (TRPV1) showed low expression, in some cases even unconclusive (Figure 14 C). Substance P (SP) was detected in some
fibers (white arrows), but also resulted in a high background signal (yellow arrow; Figure 13 D).

Figure 14: Key sensory marker expression. Expression of (A) PRPH, (B) Na\textsubscript{v} 1.8, (C) TRPV1, and (D) SP together with TUJ1. Scale bars: 50 µm. Acquired with Apotome.

Abbreviations: DAPI = 4’,6-diamidino-2-phenylindole; Na\textsubscript{v} 1.8 = sodium voltage-gated channel alpha subunit 10; PRPH = peripherin; SP = substance P; TRPV1 = transient receptor potential cation channel subfamily V member 1; TUJ1 = neuron-specific class III β-tubulin
5.7.5 TRPV1 labeling using dkTx

A secondary labeling technique using DkTx (see section 4.3.1) was used to detect TRPV1 in mature control neurons.

DkTx+ neurons were sparse in the PRPH+ population, with a substantial amount of non-cellular DkTx+ profiles present in the sample (blue arrows; Figure 15 A). A more detailed analysis revealed DkTx− (white arrow) and DkTx+ neurites (yellow arrow) likely in the same fiber bundle (Figure 15 B – D).

Figure 15: Labeling of TRPV1. (A) Overview of PRPH and DkTx labeling with some doublepositive fibers and DkTx aggregates (blue arrows). Photomicrograph-excerpts from the single acquisition channels for (B) PRPH and (C) DkTx. (D) Two-channel pictures with marked DkTx+ fiber (yellow arrow)
44

and DkTx: fiber (white arrow). Scale bars: 50 µm (A); 10 µm (B – D). All acquired with Apotome as maximum intensity Z-projections.

Abbreviations: DkTx = double-knot toxin; PRPH = peripherin

5.7.6 Marker expression of mature neurons – qRT-PCR

Expression of a small panel of key markers was investigated using qRT-PCR. In this section, data of one clone of each patient is presented; data of the second clone is shown in the supplementary (see section 8.9). Gene expression is normalized to iPSC expression (see section 4.13). A characterized control cell line was analyzed in parallel, but is lacking data for PRPH, due to insufficient amount of RNA.

Mature neurons, derived from TK8 Cl6 iPSC expressed TUJ1, PRPH, Nav 1.7, and TRPV1 (Figure 16 A). The same markers were upregulated in TK9 Cl1 neurons, compared to iPSC baseline expression (Figure 16 B).

Figure 16: Gene expression of mature neurons. Neurons from (A) TK8 clone 6 and (B) TK9 clone 1 expressed TUJ1, PRPH, Nav 1.7 and TRPV1.
5.8 Neuronal Gb3 accumulations

Mature neurons were analyzed for Gb3 depositions, together with the lysosomal-associated membrane protein 1 (LAMP1).

Gb3 accumulations colocalizing with LAMP1 were found in a perinuclear way, and to a certain extent in neurites in neurons derived from TK8-iPSC (Figure 17 A) and TK9-iPSC (Figure 17 B). No obvious difference in Gb3 load or lysosomal density was observed. Control cells showed no accumulations at all with a comparable lysosomal density as TK8 and TK9 (Figure 17 C). Deeper investigation of LAMP1+ structures (Figure 17 A’ – C’) and Gb3 depositions (Figure 17 A” – C””) revealed lysosomal localization (white arrows) of Gb3 in TK8 (Figure 17 A”’), TK9 (Figure 17 B”’), but not in control cells (Figure 17 C”’).
Figure 17: Gb3 accumulations in iPSC-derived neurons. Numerous Gb3 depositions colocalizing with LAMP1+ profiles were detected in (A) TK8 and (B) TK9 neurons. (C) The control population showed no accumulations at all, but a normal LAMP1 immunoreaction. Enlarged single channel acquisition images of LAMP1 (A', B', C'), STxB (A'', B'', C'') showing Gb3 localization inside of lysosomes (white arrows) in TK8 (A'''), TK9 (B'''), but not in (C''') control cells. Scale bars: 15 µm (A - C); 2 µm (A' - C'''). All acquired with SIM, with maximum intensity Z-projections (A – C) and single focal planes (A' – C''').
5.9 Effect of ERT on Gb3 depositions

To analyze the effect of agalsidase-β on neuronal Gb3 accumulations, 1 week old (young; Figure 18) and > 6 weeks old neurons (mature; Figure 19) were incubated and analyzed for Gb3 load (see section 4.12.3). The amount of analyzed neurons is listed in Table 3. No Gb3 accumulations at all were detected in control cells with or without treatment and thus omitted from analysis (n=150, data not shown).

Table 3: Amount of analyzed neurons.

<table>
<thead>
<tr>
<th>Accumulation subgroup</th>
<th>Cell line</th>
<th>TK8</th>
<th>TK9</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>no ERT</td>
<td>+ ERT</td>
</tr>
<tr>
<td>Young neurons (1 week old; N)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TUJ1+ cells</td>
<td></td>
<td>450</td>
<td>450</td>
</tr>
<tr>
<td>Total Gb3 load</td>
<td></td>
<td>104</td>
<td>132</td>
</tr>
<tr>
<td>Scattered Gb3 load</td>
<td></td>
<td>25</td>
<td>0</td>
</tr>
<tr>
<td>Focal Gb3 load</td>
<td></td>
<td>127</td>
<td>132</td>
</tr>
<tr>
<td>Mixed Gb3 load</td>
<td></td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Mature neurons (&gt; 6 weeks old; N)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TUJ1+ cells</td>
<td></td>
<td>1207</td>
<td>1286</td>
</tr>
<tr>
<td>Total Gb3 load</td>
<td></td>
<td>913</td>
<td>490</td>
</tr>
<tr>
<td>Scattered Gb3 load</td>
<td></td>
<td>808</td>
<td>329</td>
</tr>
<tr>
<td>Focal Gb3 load</td>
<td></td>
<td>76</td>
<td>156</td>
</tr>
<tr>
<td>Mixed Gb3 load</td>
<td></td>
<td>29</td>
<td>5</td>
</tr>
</tbody>
</table>

Abbreviations: ERT = enzyme replacement therapy; Gb3 = globotriaosylceramide; N = number; TUJ1 = neuron-specific class III β-tubulin

In young neurons from TK8 and TK9, ERT had no effect on the total Gb3 load (Figure 18 A), whereas scattered depositions were reduced in treated TK9 neurons compared to untreated (p<0.05, Figure 18 B). Focal Gb3 depositions were not cleared by ERT in TK8 cells, but increased in treated TK9 neurons compared to neurons lacking ERT (p<0.05, Figure 18 C). Mixed Gb3 depositions were decreased only in TK9 with treatment compared to untreated cells (p<0.05, Figure 18 D).
Figure 18: Effect of ERT on young neurons. (A) Total Gb3 load was not reduced in young neurons after treatment in both lines. (B) Scattered Gb3 accumulations were decreased in TK9 young neurons after ERT, but not in TK8 (p<0.05). (C) Focal Gb3 depositions were increased in young neurons with ERT, but not changed in TK8 (p<0.05). (D) Mixed Gb3 loads were reduced in TK9, but not in TK8 (p<0.05).

For number of evaluated neurons see Table 3.

Abbreviations: ERT = enzyme replacement therapy; Gb3 = globotriaosylceramide; TUJ1 = neuron-specific class III β-tubulin

Total Gb3 load was decreased in treated neurons derived from TK8-iPSC (p<0.001), with TK9 neurons showing a trend towards reduction compared to untreated cells (p=0.071; Figure 19 A). The same was true for scattered Gb3 depositions, the most common form of accumulations (Figure 19 B). No effect of ERT was found on focal Gb3 depositions (Figure 19 C), but a decrease was detected in cells with a mixed Gb3 load for TK8 compared to untreated neurons (p<0.05; Figure 19 D).
Figure 19: Effect of ERT on mature neurons. (A) Total Gb3 load was reduced in TK8 neurons after ERT (p<0.001). Gb3 depositions in TK9 neurons showed a trend of reduction after treatment (p=0.071). (B) Scattered accumulations were reduced in TK8 (p<0.001), not in TK9 (p=0.071), similar to (A). (C) No effect on focal Gb3 accumulations was found in TK8 and TK9 neurons. (D) Mixed Gb3 deposition were reduced after treatment in TK8 (p<0.05), but not in TK9 neurons.

For number of evaluated neurons see Table 3.

Abbreviations: ERT = enzyme replacement therapy; Gb3 = globotriaosylceramide; TUJ1 = neuron-specific class III β-tubulin

Young and mature neurons were compared with each other to analyze time-dependent build-up of Gb3 accumulations (Figure 20, Figure 21).

In untreated TK8 neurons, total Gb3 load was higher in mature neurons without ERT, but not with ERT (p<0.01; Figure 20 A). More cells with scattered Gb3 accumulations were found with or without treatment in mature neurons (p<0.01; Figure 20 B), whereas young neurons had more focal Gb3 depositions, independent of treatment (p<0.01, p<0.05; Figure 20 C). Cells with mixed Gb3 accumulation were sparse and showed no time-dependent difference (Figure 20 C).
Figure 20: Time dependent accumulation of Gb3 in TK8 neurons. (A) Total Gb3 load was increased in mature neurons without ERT (p<0.01), no difference was detected after ERT. (B) Scattered depositions were increased with, and without treatment (p<0.01). (C) Focal Gb3 was increased in young neurons, independent of treatment (p<0.01, p<0.05). (D) No differences were detected in cells with mixed Gb3 load.

For number of evaluated neurons see Table 3.

Abbreviations: ERT = enzyme replacement therapy; Gb3 = globotriaosylceramide; TUJ1 = neuron-specific class III β-tubulin

Similar to TK8 neurons, mature TK9 neurons had a higher total Gb3 load without treatment than young neurons (p<0.05, Figure 21 A). Scattered accumulations were more prominent in older neurons without ERT and a trend in the same direction was found in cells with ERT (p<0.05, p=0.057; Figure 21 B). Focal Gb3 load was more abundant in young neurons without treatment than in treated neurons (p<0.05, p=0.057; Figure 21 C). As in TK8 neurons, cells with mixed Gb3 depositions were rare with no age-differences (Figure 21 D).
Figure 21: Time dependent accumulation of Gb3 in TK9 neurons. (A) Total Gb3 load was increased in mature neurons without treatment (p<0.05). (B) Scattered depositions were also increased in old neurons without ERT (p<0.05). (C) Focal Gb3 accumulations were increased in young neurons without treatment (p<0.05). (D) No changes were detected in cells with a mixed Gb3 load.

For number of evaluated neurons see Table 3.

Abbreviations: ERT = enzyme replacement therapy; Gb3 = globotriaosylceramide; TUJ1 = neuron-specific class III β-tubulin

5.10 Effect of TNF on neuronal Gb3 accumulations

As a pilot experiment, mature neurons from TK8 Cl6 were incubated with TNF or trehalose as control and Gb3 load was assessed to model inflammation as a typical pain trigger in FD patients (Üçeyler et al., 2019). Gb3 load did not change after incubation with TNF compared to trehalose treatment (Figure 22).
**Figure 22: Effect of TNF on Gb3 depositions.** No difference of Gb3 load was detectable when treating neurons with TNF and trehalose.

Abbreviations: Gb3 = globotriaosylceramide; TNF = tumor necrosis factor-α; TUJ1 = neuron-specific class III β-tubulin

5.11 Confocal Ca\(^{2+}\) imaging

Mature neurons from TK8 (Figure 23), TK9 (Figure 24), and the control (Figure 25) were analyzed at physiological conditions (37°C, 5% CO\(_2\) [v/v]) using confocal Ca\(^{2+}\) imaging for detection of intracellular calcium responses.

Loading of neurons with Fluo-8 AM dye was successful (Figure 23 A; Figure 24 A; Figure 25 A). Repetitive temporal changes of the fluorescence intensity of single neurites (white arrows), were detected, cycling from high (Figure 23 A'; Figure 24 A'; Figure 25 A'), over low (Figure 23 A''; Figure 24 A''; Figure 25 A''), to high again (Figure 23 A'''; Figure 24 A'''; Figure 25 A'''). Analysis with NA\(^3\) software confirmed repeated spiking of the mean intensity values, indicating neuronal activity (Figure 23 B; Figure 24 B; Figure 25 B).

No comparative analysis between cell lines was performed (see section 6.6).
Figure 23: Ca\(^{2+}\) imaging of TK8 neurons. (A) Confocal overview image of Fluo-8 AM loaded neurons. (A’ – A’’) Cropped images of a single neurite (white arrow) at different timepoints (1-3). (B) Corresponding mean fluorescence intensity readouts of the region of interest showing repetitive cycling. Scale bars: 50 µm (A); 15 µm (A’ – A’’). All acquired with CLSM.
**Figure 24: Ca²⁺ imaging of TK9 neurons.** (A) Confocal overview image of Fluo-8 AM loaded neurons. (A’ – A”’) Cropped images of a single neurite (white arrow) at different timepoints (1-3). (B) Corresponding mean fluorescence intensity readouts of the region of interest showing repetitive cycling. Scale bars: 50 µm (A); 15 µm (A’ – A”’). All acquired with CLSM.
Figure 25: Ca²⁺ imaging of Ctrl neurons. (A) Confocal overview image of Fluo-8 AM loaded neurons. (A’ – A’’) Cropped images of a single neurite (white arrow) at different timepoints (1-3). (B) Corresponding mean fluorescence intensity readouts of the region of interest showing repetitive cycling. Scale bars: 50 µm (A); 15 µm (A’ – A’’). All acquired with CLSM.
5.12 Patch clamp analysis of mature neurons

Neurons from all cell lines initiated AP after stimulation (Figure 26 A, B, C). We measured resting membrane potential, the threshold to elicit an AP and calculated the difference ($V_{\text{ThresholdDiff}}$) as a marker for neuronal excitability (Figure 26 D). Neurons from TK8 had a lower $V_{\text{ThresholdDiff}}$ compared to control (p<0.05) or TK9 neurons (p<0.001; Figure 26 E).
Figure 26: Patch clamp analysis of control, TK8, and TK9. Examplified AP trains for (A) TK8, (B) TK9, and (C) control neurons. (D) Definition of the $V_{\text{ThresholdDiff}}$, shown on an AP. (E) TK8 had lower $V_{\text{ThresholdDiff}}$, compared to TK9 ($p<0.001$) and control neurons ($p<0.05$).

Abbreviations: AP = action potential; Data acquisition and analysis performed by Dr. Lukas Hofmann

5.13 dSTORM: Proof-of-Principle

As a Proof-of-Principle experiment, control neurons were labelled with CTxB and analyzed using the dSTORM setup. The super-resolution image reveals many details of the membrane, with virutally no background signal (Figure 27 A, A’), whereas these details are lost using conventional widefield microscopy (Figure 27 B, B’)

Figure 27: dSTORM microscopy of control neurons. Overview of (A) reconstructed dSTORM photomicrograph, in comparison with (B) conventional widefield recording of a CTxB labelled neuron. Close-up comparison of (A’) dSTORM and (B’) widefield technique. Scale bars: 5 µm (A, B); 500 nm (A’, B’).

Abbreviations: CTxB = Cholera toxin, B subunit; dSTORM = direct stochastic optical reconstruction microscopy; Data acquisition by Jan Schlegel (M.Sc.).
6 Discussion

6.1 Summary of main results

The main goal of our study was to establish an *in vitro* disease model for FD, based on biomaterial obtained from patients with a diverse pain phenotype and investigate the underlying cellular mechanisms of FD-associated pain and small fiber pathology. We generated fully characterized iPSC lines from a female (Klein et al., 2018) and two male patients. We derived neurons, expressing key sensory markers on the protein and the RNA level, showing pathognomonic Gb3 accumulations, neural activity, and electrophysiological differences, likely caused by functional alterations of ion channel activity. Challenging TK8 neurons with TNF, a typical trigger for FD pain (Üçeyler et al., 2019) did not change neuronal Gb3 load in a pilot experiment. Mature iPSC-derived neurons showed age-dependent Gb3 accumulation patterns and responded to pharmacological intervention by ERT with reduction in total Gb3 load. We further succeeded in visualizing Gb3 within neuronal lysosomes, which was not shown before. Additionally, we introduced a highly specific TRPV1-labeling and showed that our neurons are suitable for state-of-the-art analysis using dSTORM and SIM microscopy.

6.2 iPSC-derived sensory neurons as a potent tool in pain research

Modelling pain *in vitro* is a challenge since pain is a subjective experience and the perceived intensity has a high inter-individual variability (Cohen et al., 2018). However, to investigate potential mechanisms underlying pain, *in vitro* systems are still a valuable tool allowing assessment of pain-associated parameters, such as neuronal excitability (Chung and Chung, 2002), spontaneous activity (Xie et al., 2005), and firing rate (Yang et al., 2018). *In vitro* tools are increasingly established and applied in diverse research fields such as psychiatric disorders (Noh et al., 2017), neurodegenerative diseases (Li et al., 2018), and also pain syndromes (Eberhardt et al., 2015). In a recent study, patient-specific iPSC-derived sensory neurons provided a suitable basis to identify pharmacological treatment options against refractory pain (Namer et al., 2018). Analysis of sensory neurons derived from iPSC with a pathological Na\(_v\) 1.7 mutation, a major ion channel involved in pain (Kretschmer et al., 2002), revealed higher spontaneous activity compared to wildtype cells based on microelectrode array experiments. Application of the anticonvulsant lacosamide resulted in reduced spontaneous firing *in vitro* and relieved pain in the
patient (Namer et al., 2018). Another example for the usefulness of patient-derived sensory neurons in pain research is the investigation of the diverse phenotypes in patients with the same disease-associated mutation. A family carrying a pathogenic Na\textsubscript{v} 1.7 mutation causing inherited erythromelalgia, but with diverse pain profiles was investigated using individual iPSC-derived sensory neurons (Mis et al., 2018). Applying whole genome sequencing the authors found a patient-specific mutation in a pain modulating gene, which contributed to interindividual differences in nociception \textit{in vitro} and \textit{in vivo} (Mis et al., 2018). Congenital insensitivity to pain caused by loss-of-function mutations in the gene encoding Na\textsubscript{v} 1.7 was investigated using iPSC-derived sensory neurons revealing that Na\textsubscript{v} 1.7 is a key regulator of neuronal excitability and that blockers for this channel currently in clinical trials lack specificity (McDermott et al., 2019). These examples show that utilizing iPSC and their downstream applications may help to elaborate personalized treatment options and investigate patient-specific phenotypes.

For FD, iPSC-based disease models are still rare. The first patient specific FD-iPSC line was published in 2013 showing membranous cytoplasmic bodies, but subsequent differentiation into mature cells was not successful, likely due to intracellular alterations by Gb3 (Kawagoe et al., 2013). iPSC derived cardiomyocytes of FD patients were successfully used to investigate the efficacy of substrate reduction therapy on Gb3 clearance (Itier et al., 2014) and establish a high-content analysis-based drug screening platform (Kuramoto et al., 2018). Still, there are no studies using \textit{in vitro} models for FD pain research; the X-linked nature of FD may be one reason, a major challenge in iPSC research (Dandulakis et al., 2016).

6.3 Suitability of iPSC from female patients for disease modelling

Epigenetic mechanisms, such as methylation or acetylation lead to gene silencing or activation, respectively. During X-chromosomal inactivation (XCI), histone methylation leads to the formation of heterochromatin, blocking transcription of most genes from one X-chromosome (X\textsubscript{i}), but leaving the other X-chromosome active (X\textsubscript{a}) and usually results in a 50:50 or 60:40 XCI in healthy individuals (Chow et al., 2005). As described (see section 3.2.1), reprogramming to iPSC leads to remodeling of the epigenome, also affecting the XCI pattern in these cells. The mechanism of XCI during reprogramming is still under investigation, but studies either point towards a reactivation of the once silenced X-chromosome and thus leading to a novel
X<sub>a</sub>X<sub>i</sub>/X<sub>a</sub>X<sub>a</sub> distribution (Lagarkova et al., 2010) or a retained XCI pattern, originating from the somatic cells to be reprogrammed (Tchieu et al., 2010). These contradictory findings may be the result of biological variability of the cells during reprogramming (Bruck and Benvenisty, 2011). Long-term cultivation of iPSC might also have an impact on XCI, leading to an erosion of the inactivation pattern in favor of one chromosome, resulting in a 100:0 XCI distribution (Mekhoubad et al., 2012).

Our late FD-iPSC (p>5) derived from a female FD patient showed a skewed XCI with a ratio of 100:0 which is in line with the mentioned literature. Due to the presence of Gb3 accumulations in early (p<5) and the absence of accumulations in late FD-iPSC, we speculate that erosion of XCI developed over time, leading to a homogenous population of X<sub>a</sub>X<sub>i</sub>, and not X<sub>a</sub>X<sub>i</sub>/X<sub>a</sub>X<sub>i</sub> cells. Although, it cannot be determined which chromosome is favored during XCI in this case, the lack of Gb3 accumulations and the absence of mutated GLA on a transcriptomic level strongly suggests a complete inactivation of the X-chromosome carrying the disease-associated mutation. Paternal DNA is needed to reach cytogenetic proof. Another mechanism, yet less likely than XCI erosion, is a potential selective disadvantage of cells carrying mutated GLA, leading to a selection for healthy cells in vitro.

These findings need to be considered when iPSC are used for X-linked disease modelling, an ongoing field of investigation (Cheung et al., 2012). A possible approach to generate homogenous disease cell lines could be to utilize FACS and sorting cells early after reprogramming for their phenotype based on a reliable marker. In FD, STxB could be used to distinguish and isolate cells with Gb3 accumulations or increased membrane-bound Gb3. This would eliminate any evolutionary pressure in heterogeneous cell populations, although the challenge of eroding XCI persists. When using such cell lines, close monitoring is needed to ensure that the desired phenotype is present in vitro (Dandulakis et al., 2016). For downstream differentiation experiments, affected and healthy cells from the same patient could be cultivated together for a limited time to mimic the in vivo distribution. For male patients, XCI does not play a role and thus simplifies the establishment of new protocols and the downstream analysis.
6.4 iPSC and iPSC-derived sensory neurons from male FD patients

We did not find any differences in the proliferation properties or cell viability of iPSC or neurons between the control line and the FD lines. In terms of morphology or total Gb3 load, no differences were found between a patient with (TK8) and without (TK9) pain. Both showed a similar distribution of neuronal Gb3 accumulations and mature (i.e. > 6 weeks) cells responded well to ERT whereas cells from the control line showed no Gb3 accumulations at all. We used patients with two different nonsense mutations to test our disease model in a worst-case scenario: almost a complete lack of functional GLA, as reflected by pathologically reduced GLA-activity \textit{in vivo} (see Table 1). Nonetheless, our model can also be used to investigate the effect of missense mutations, which is of particular interest in finding new therapeutic approaches, or mutations responding to chaperone therapy (Giugliani et al., 2013).

Generating patient-specific sensory neurons offers the possibility to investigate the response to novel pharmacological compounds not only on the Gb3 load, but also on electrophysiological properties of the affected neurons. This system can be used to evaluate patient-specific alterations in neuronal activity, treat the neurons \textit{in vitro} with a suitable drug, and transfer this knowledge to the patient in a bench-to-bedside approach (Namer et al., 2018).

6.5 Pharmacological response and Gb3 accumulations

A suitable \textit{in vitro} disease model not only mimics disease phenotype, but also responds to common therapies, such as reduction of cellular Gb3 load by ERT (Itier et al., 2014). Our mature FD neurons showed the expected decrease of Gb3 accumulations upon incubation with exogenous GLA, making it an applicable model to investigate the effect of drugs on intraneuronal Gb3 depositions. Interestingly, we found different patterns of Gb3 accumulations depending on the duration of cultivation. While in young neurons (i.e. 1 week old), Gb3 was focally distributed, mature neurons mainly showed scattered Gb3. The latter was cleared by ERT, indicating that exogenous GLA can enzymatically break down and thus reduce Gb3 load in these cells. Focal accumulations, however, were resistant to treatment in young and mature neurons. Although this may be an artifact of our \textit{in vitro} model, it also may have relevance for the \textit{in vivo} situation since diversity in treatment response is a frequent clinical observation and it was shown that distinct Gb3 isoforms are resistant to ERT in kidney cells (Kodama et al., 2017).
Another interesting question is, if these focal Gb3 accumulations are also localized inside individual lysosomes, as we showed using SIM for scattered depositions. Gb3 was also found outside lysosomes, which may point towards lysosomal rupture, due to a Gb3 overload and might influence cellular dynamics (Hsu et al., 2019).

In a pilot experiment, we challenged our neurons with TNF, to simulate an inflammatory environment, known to increase the Gb3 load in white blood cells (Üçeyler et al., 2019). It is known that TNF, amongst other pro-inflammatory cytokines forms a positive-feedback loop with Gb3, which results in an increased Gb3 expression caused by TNF (Eisenhauer et al., 2001) and vice versa (Sakiri et al., 1998). Since fever is a major trigger of FD pain, a link between TNF, Gb3, and pain is likely. We aimed at investigating the effect of TNF on the Gb3 load, to see if this feedback-loop also exists in our neurons. We speculated that an increase of Gb3, induced by TNF can lead to abnormal neuronal activity, caused by an upregulation of nociceptive ion channels, as it was shown in old GLA KO mice (Lakoma et al., 2016). We did not detect an effect of TNF on Gb3, which may be due to several factors. First, it is known that iPSC-derived neurons resemble tissue of the first trimester of embryogenesis (Mariani et al., 2012); hence, TNF might activate different pathways not related to Gb3 accumulation than in adult neurons. Second, we did not investigate the expression of the TNF receptor 1 on our neurons, known to be expressed on sensory neurons (Li et al., 2004). A lack of this receptor could explain the unresponsiveness of our neurons. Third, Gb3 accumulations did change during TNF treatment in individual cells, e.g. more accumulations per cell, but were not reflected by our assay, because we only quantified positive cells, but not the individual cellular load. A workaround for this problem might be utilization of deep learning tools, such as DeepFLASH (Segebarth et al., 2018), to automatize and maximize data output. Finally, this was a pilot experiment and we used the TNF concentration and incubation time suitable for white blood cells (Üçeyler et al., 2019), which likely have to be adapted to this system.

6.6 Electrophysiological properties of iPSC-derived sensory neurons
Functional testing of iPSC-derived sensory neurons using confocal Ca$^{2+}$ imaging revealed rhythmic fluctuations of intracellular Ca$^{2+}$ levels, strongly suggesting spontaneous firing and organized network activity (O'Donovan et al., 1994). To maximize contrast and minimize out-of-focus fluorescence, we decided to use a
CLSM for data acquisition. A drawback of this method is a low sampling rate of 0.25 Hz, which made detection of single APs with a duration of <5 ms impossible. We aimed at investigating binned action potentials (Davies et al., 2019) over a period of 8 min. Subsequent analysis using NA\textsuperscript{3} software (Prada et al., 2018) showed that a sampling rate of 0.25 Hz was too low for effective analysis. Still, the collected data strongly suggests spontaneous network activity in all analyzed cell lines, indicating viable neuronal cultures, suitable for live-cell imaging experiments.

Patch clamp analysis revealed a decreased AP threshold difference ($V_{ThresholdDiff}$) in neurons from TK8 (patient with pain), compared to TK9 (patient without pain), and healthy control cells. $V_{ThresholdDiff}$ is determined to describe the degree of excitability of neurons in relation to the resting membrane potential. A lower $V_{ThresholdDiff}$ means that a smaller stimulus is required to initiate APs, which was the case for cells from the patient with FD pain. In vivo, this may result in a hyperexcitability of nociceptors and thus lead to pain (Ratte and Prescott, 2016). Upon stimulation, the Na\textsubscript{v} 1.1, 1.2, 1.3, 1.6, and 1.9 channels depolarize the membrane until the AP threshold is reached, which triggers the opening of Na\textsubscript{v} 1.7, the AP threshold defining channel (Meents et al., 2019). Altered steady-state kinetics, for example hyperpolarized activation, or depolarized inactivation of Na\textsubscript{v} 1.7 may be the cause for the reduced AP threshold, leading to a more easily excitable neuron. It was also shown in vitro that an increased Gb3 load in human embryonic kidney 293 (HEK) cells expressing Na\textsubscript{v} 1.7 had lower sodium currents compared to HEK cells with a normal Gb3 load. This effect was recovered by ERT incubation, directly linking Na\textsubscript{v} 1.7 and Gb3 (Hofmann et al., 2018).

The mechanisms underlying reduced $V_{ThresholdDiff}$ are still elusive, but a direct link between Gb3 and Na\textsubscript{v} 1.7 provides a starting point for further investigations, e.g. by using colocalization studies with super-resolution microscopy to investigate Gb3 - ion channel interactions on the membrane of iPSC-derived neurons. It was shown in the GLA KO mouse model of FD that an increased Gb3 load in aortic endothelial cells leads to a downregulation of the Ca\textsuperscript{2+} gated potassium channel K\textsubscript{Ca}3.1 by clathrin mediated endocytosis (Choi et al., 2014). Despite the fact that this was found using murine, non-neuronal cells, it still indicates that Gb3 may have a direct influence on the ion channel composition of membranes, likely also in neurons.
Lacking single ion channel investigations, the reason for the altered $V_{\text{ThresholdDiff}}$ is still unknown, but indicates that our *in vitro* model not only mimics the Gb3 accumulation phenotype, but also reflects electrophysiological changes in affected neurons. Identifying the altered ion channels will be an important step towards a more personalized analgesic treatment for patients with FD.

6.7 Labeling of Gb3 and TRPV1

To improve labelling of Gb3 for downstream optical analysis, we used dye-conjugated STxB (Majoul et al., 2002). This toxin is known to specifically bind to Gb3 (Hughes et al., 2000) and to some extent Gb4, but with a much lower affinity (Zumbrun et al., 2010). A major advantage of STxB is its specificity, resulting in labelling experiments with virtually no background signal, making it a suitable approach for demanding imaging techniques, such as dSTORM or SIM. Furthermore, STxB can easily be used to detect membrane bound Gb3 and utilized in a live-cell imaging environment to visualize the endoplasmic reticulum, due to its intracellular trafficking route (Yu and Haslam, 2005). One drawback of this method is the detection of Gb4 in addition to Gb3, which makes it impossible to differentiate both. We still decided to identify STxB$^+$ profiles as Gb3, due to the 3-fold higher affinity of STxB for Gb3 (Gallegos et al., 2012). Furthermore, it was shown that Gb4 was not increased in GLA KO mice, compared to wildtype littermates in an *in vitro* rodent model of primary aortic endothelial cells (Shu et al., 2005). Together with the complete absence of STxB$^+$ accumulations in control skin, iPSC, and neurons, we hypothesized that if Gb4 is present in our cells, its concentration is most likely below the detection threshold of our assay and hence of minor relevance.

We also introduced a new approach to visualize TRPV1, a major player in nociception (Immke and Gavva, 2006). Despite numerous commercial antibodies available against TRPV1, in our hands the immunoreactions showed a high background signal and some unspecific binding, making the analysis unreliable. By utilizing the selectivity of DkTx for TRPV1 as agonist (Bohlen et al., 2010), combined with an N-terminal His$_6$-Tag, we were able to selectively label TRPV1$^+$ fibers, using a highly specific anti-His$_6$-antibody. Besides its selectivity, a major advantage of this approach is its suitability for live-cell imaging. It is possible to incubate and visualize neurons live with the toxin and simultaneously investigate neuronal activity, caused by TRPV1 activation using Ca$^{2+}$ imaging. As a caveat, excitotoxicity caused by
irreversible binding of the toxin and increased Ca\textsuperscript{2+} influx (Choi, 1988) need to be taken into account.

6.8 Improved sensory differentiation protocol

We used published differentiation protocols as basis for our approach (Chambers et al., 2012; Eberhardt et al., 2015) and established a refined procedure to maximize reliability and neuronal survival. Current protocols aim at generating a highly purified sensory neuron culture early on, with as few non-neuronal cells as possible by using mitomycin C as cytostatic to effectively eliminate all mitotic cells. After initial experiments, we chose FdU because of better neuronal survival (Hui et al., 2016). In our hands, FdU routinely led to the formation of a feeder-layer. This is beneficial for neurons in terms of adhesion to cells, instead of an artificial extracellular matrix, but also for media composition (Petschnik et al., 2011). Mimicking the in vivo situation, where neurons also grow in symbiosis with e.g. glial cells (Stevens, 2003), our neurons are cultivated in a heterogeneous system, consisting of the desired neurons and cells supporting neuronal survival. The exact composition of this feeder-layer remains elusive and an in-depth characterization is needed. Nonetheless, we observed that neuronal viability was more robust in cultures with this feeder-layer, compared to pure neuronal cultures. We also chose to change the medium as few as possible to minimize physical (LaPlaca and Thibault, 1997), osmotic (Brocker et al., 2012) and nutrient (Young et al., 2009) stress on the neurons. One disadvantage of this method is the relative heterogeneity of our neuronal cultures, although the feeder-layer itself tends to degenerate during long-term cultivation and can be further depleted by replating mature neurons in the presence of FdU. A "contamination" with non-neuronal cells might be a challenge for highly sensitive assays, such as qRT-PCR or RNA sequencing (Wang et al., 2019). Still, with our system, iPSC-derived sensory neurons are robustly generated and maintained for at least eight weeks, expensive media consumption and hands-on time is minimized. Our neurons can be cultivated in a large scale and replated for the desired analysis in smaller cultivation vessels, making it a viable tool for pain research, not only for FD, but diseases affecting the PNS in general.

6.9 The diversity of pain in FD and experimental therapies

The pain phenotype in FD is diverse (Üçeyler et al., 2014), with the underlying mechanisms still under investigation. Although it is accepted that Gb3 plays a major
role in FD pain, there are conflicting results regarding reduction of the Gb3 load via ERT and pain relief. It was shown in several studies that ERT did not change pain intensity in adults (Eng et al., 2001b; Wilcox et al., 2004; Vedder et al., 2007; Üçeyler et al., 2014), whereas other studies reported pain reduction after ERT (Schiffmann et al., 2001; Hilz et al., 2004; Watt et al., 2010), and others reported some analgesic effect in children treated with ERT (Ries et al., 2006; Ramaswami et al., 2007). A possible explanation for the analgesic efficacy of ERT in children can be a long-term effect of Gb3 on post-mitotic cells, such as neurons, leading to permanent cellular changes, which cannot be reversed by ERT in adults. In children, however, neural plasticity is much more pronounced (Moore and Murphy, 2016) and early ERT might reverse these effects, thus alleviating pain. Furthermore, it was reported that patients with an early intervention with ERT have a better clinical outcome than patients who started treatment late (Germain et al., 2015). This further points towards time-dependent pathological cellular changes, which may be reversed by reducing Gb3 as soon as possible.

Even in families carrying the same mutation in GLA, the disease phenotype is differing from one individual to another. A case study reports on two brothers, genetically identical for GLA, with no enzyme activity at all with the younger brother having severe symptoms, whereas the older one is asymptomatic (Cammarata et al., 2015). Such constellations make a phenotype-genotype correlation difficult. The underlying mechanisms of these diverse phenotypes are still elusive, but it is of note that the screening for mutations only in GLA might not be sufficient and leaves other disease-associated genomic changes undetermined. A recent study used whole-exome sequencing of iPSC-derived sensory neurons to investigate inherited erythromyelalgia and its diverse pain phenotype. It was shown that the moderately affected mother had a mutation on a pain modulating gene, additionally to the familial Na\textsubscript{v} 1.7 mutation, known to cause erythromyelalgia. This additional mutation led to a downregulation of neuronal excitability in the mother, thus decreased pain, compared to the severely affected son, lacking this mutation (Mis et al., 2018). The combination of whole exome sequencing and patient-derived sensory neurons might be a viable tool to detect further mutations and their effects on neuronal excitability.

Besides genomic mutation, it has been discussed that the epigenome might play a role in the manifestation of different disease phenotypes caused by the same
It has been shown that the epigenome is highly flexible and can easily be altered, e.g. by a dietary change (Zhang and Kutateladze, 2018), physical activity (Blackburn et al., 2015), chronic pain (Liang et al., 2015), but also environmental factors such as metal exposure (Takiguchi et al., 2003) or air pollution (Yauk et al., 2008). The transition in some patients from acute to chronic pain after injury for example, is suspected to be a result of epigenetic remodeling during the acute pain phase (Buchheit et al., 2012). Diverse epigenomes between individuals carrying the same disease-associated mutation can thus be a major player in pain severity. For models based on iPSC, this is a challenge, because during reprogramming, the epigenome is severely altered to achieve pluripotency (Godini et al., 2018), thus potentially erasing pain-relevant epigenetic information.

A hallmark of FD is the triggerable pain by physical activity, thermal stimuli, and fever (Politei et al., 2016). These triggers have in common that they result in an elevated generalized body temperature (fever, activity) or locally elevated and/or reduced body temperature (thermal stimuli). A major heat sensing ion channel is TRPV1 (Voets et al., 2004), causing pain upon activation. It was shown in the GLA KO mouse model that the protein expression of TRPV1 is elevated in mice (Lakoma et al., 2016) and that they show heat hypersensitivity upon TRPV1 activation in contrast to wildtype animals (Hofmann et al., 2018). It was also shown that TRPM8, a cold sensing ion channel (Liu and Qin, 2011), is downregulated (Lakoma et al., 2014) and Naᵥ 1.8, an ion channel involved in neuropathic pain (Amir et al., 2006), is upregulated in GLA KO mice (Lakoma et al., 2014). This points towards an altered ion channel expression on affected neurons. An increased expression of TRPV1 on nociceptors might lead to hyperexcitability due to temperature changes, caused by an elevated body temperature and thus result in pain. Furthermore, proalgesic inflammatory factors are known to reduce the thermal threshold of TRPV1 (Velisetty et al., 2017), linking fever and heat induced pain (Velisetty et al., 2017). Our in vitro model can be used to investigate temperature differences, proalgesic agents, and their effect on pain, e.g. by electrophysiologically (Ca²⁺ imaging or patch clamp) recording neurons at a baseline temperature, followed by a temperature increase / incubation with a proalgesic agent and comparing parameters, such as firing frequency, spontaneous activity, VThresholdDiff of both conditions. Applying selective ion channel blockers can then be used to identify the causal ion channel.
ERT and chaperone therapy, the latter one not being suitable for all mutations are the only available therapeutic options for FD, creating demand for new approaches, such as gene therapy or other sources for GLA. Gene therapy for FD is already in clinical trials, with the advantage that no exogenous GLA is needed, because the genetic defect in GLA is corrected using lentiviral vectors *ex vivo* in hematopoietic stem cells and transplanted back into the patient. These cells and their daughter cells secrete functional GLA, which is taken up by GLA deficient cells, reducing Gb3 load, without the need of biweekly ERT. This therapeutic option is currently being evaluated in a phase II clinical trial (https://clinicaltrials.gov/; Identifier: NCT03454893).

A major problem of ERT can be the formation of neutralizing anti-drug antibodies (Mauhin et al., 2015), produced by the patient as reaction to exogenous GLA, manufactured in mammalian cell systems, which can greatly reduce the efficiency of ERT (Lenders et al., 2016). Recently, the plant-derived α-galactosidase A1.1 was discovered which efficiently lowered lyso-Gb3 levels in FD fibroblasts (Kytidou et al., 2018). It was also shown that A1.1 was delivered into lysosomes, did not cross-react with neutralizing antibodies, and is much more cost efficient, allowing application of higher dosages to increase organ penetration, making it a promising approach for FD (Kytidou et al., 2018). GLA extracted from the moss *Physcomitrella patens* is another approach to prevent immune-mediated reduction of ERT efficiency. Moss-derived GLA was well tolerated and a single dose resulted in a prolonged reduction of urinary Gb3 and plasma lyso-Gb3 concentrations after 28 days in a phase I clinical study (Hennermann et al., 2019). These, and future experimental approaches can be tested in our *in vitro* system for its efficiency of neuronal Gb3 depletion.

6.10 Conclusion and outlook

Our initial aim was to investigate possible differences of sensory neurons in patients with a varying pain phenotype by using the iPSC technology. We succeeded in generating and characterizing iPSC from a female, and two male patients, establish a reliable differentiation protocol and generate patient-specific sensory neurons. We showed that our FD-neurons reconstitute the disease phenotype and respond to ERT and adapted state-of-the-art methods for neuronal analysis and with these, unveiled new insights into cellular localization of Gb3, which can now be explored in more detail. Furthermore, we showed that neurons from a patient with pain differ in their
electrophysiological properties compared to neurons from a patient without pain, making a direct connection between our *in vitro* model and the clinical symptoms. Future work will be the extended super-resolution imaging of Gb3 accumulations and their potential influence on ion channel activity and cellular processes, leading to hyperexcitability and denervation. Microscopically, we aim at visualizing the pathological effect of Gb3 in neurons in a live-cell imaging environment. Electrophysiologically, Ca$^{2+}$ imaging protocols will be optimized and pharmacological investigations using patch-clamp techniques are needed to pinpoint altered neuronal firing properties to individual ion channels and thus offer therapeutic options, which can then be tested in our *in vitro* system. To increase output and move forward towards a more personalized analgesic treatment for FD patients, experiments using microelectrode arrays should be considered to simultaneously test multiple drug candidates (Scelfo et al., 2012) and read-out their effect on the electrophysiology of sensory neurons respectively on FD-associated pain.
7 References


## Appendices

### 8.1 Media for cultivation

Table 4: Media for differentiation and maturation

<table>
<thead>
<tr>
<th>Medium / Supplement</th>
<th>Final concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>KSR medium</strong></td>
<td></td>
</tr>
<tr>
<td>KnockOut™ DMEM/F-12</td>
<td></td>
</tr>
<tr>
<td>KnockOut™ Serum Replacement</td>
<td>15 %</td>
</tr>
<tr>
<td>GlutaMAX™</td>
<td>2 mM</td>
</tr>
<tr>
<td>2-Mercaptoethanol</td>
<td>100 µM</td>
</tr>
<tr>
<td>MEM NEAA solution</td>
<td>1X</td>
</tr>
<tr>
<td>Pen/Strep solution</td>
<td>1X</td>
</tr>
<tr>
<td><strong>N-2 medium</strong></td>
<td></td>
</tr>
<tr>
<td>DMEM/F12 + GlutaMAX™</td>
<td></td>
</tr>
<tr>
<td>B27-Plus Supplement</td>
<td>1X</td>
</tr>
<tr>
<td>N-2 Supplement</td>
<td>1X</td>
</tr>
<tr>
<td>Pen/Strep solution</td>
<td>1X</td>
</tr>
<tr>
<td><strong>2i cocktail</strong></td>
<td></td>
</tr>
<tr>
<td>LDN-193189</td>
<td>100 nM</td>
</tr>
<tr>
<td>SB-431542</td>
<td>10 µM</td>
</tr>
<tr>
<td><strong>5i cocktail</strong></td>
<td></td>
</tr>
<tr>
<td>LDN-193189</td>
<td>100 nM</td>
</tr>
<tr>
<td>SB-431542</td>
<td>10 µM</td>
</tr>
<tr>
<td>SU-5402</td>
<td>10 µM</td>
</tr>
<tr>
<td>DAPT</td>
<td>10 µM</td>
</tr>
<tr>
<td>CHIR 99021</td>
<td>3 µM</td>
</tr>
<tr>
<td><strong>Maturation medium</strong></td>
<td></td>
</tr>
<tr>
<td>N-2 medium</td>
<td></td>
</tr>
<tr>
<td>BDNF</td>
<td>20 ng/ml</td>
</tr>
<tr>
<td>GDNF</td>
<td>20 ng/ml</td>
</tr>
<tr>
<td>βNGF</td>
<td>20 ng/ml</td>
</tr>
<tr>
<td>Ascorbic acid</td>
<td>200 ng/ml</td>
</tr>
</tbody>
</table>

For abbreviations see page 94.
8.2 Reagents

Aqua-Poly/Mount: Polysciences, Warrington, PA

BSA: Sigma-Aldrich, St. Louis, MS, USA

ProLong™ Glass Antifade Mountant: Thermo Fisher Scientific, Waltham, MA; USA

DAPI: Sigma-Aldrich, St. Louis, MS, USA

Scandicain® 2%: AstraZeneca, London, UK

Cell culture base media:

- DMEM/F-12: Thermo Fisher Scientific, Waltham, MA; USA
- DMEM/F-12 + GlutaMAX™: Thermo Fisher Scientific, Waltham, MA; USA
- KnockOut™ DMEM/F-12: Thermo Fisher Scientific, Waltham, MA; USA
- StemMACS™ iPS-Brew XF, human: Miltenyi Biotec, Bergisch Gladbach, Germany
- NutriStem® hPSC XF: Biological Industries, Kibbutz Be’er-Haemek, Israel

Cell culture supplements / growth factors:

- 2-Mercaptoethanol: Thermo Fisher Scientific
- N-2 Supplement: Thermo Fisher Scientific, Waltham, MA; USA
- B-27™ Plus Supplement: Thermo Fisher Scientific, Waltham, MA; USA
- DMSO Hybri-Max™: Sigma-Aldrich, St. Louis, MS, USA
- FCS: Merck, Darmstadt, Germany
- KnockOut™ Serum Replacement: Thermo Fisher Scientific, Waltham, MA; USA
- Penicillin/Streptomycin: Thermo Fisher Scientific, Waltham, MA; USA
- StemMACS™ iPS-Brew XF, human, 50X Supplement: Miltenyi Biotec, Bergisch Gladbach, Germany
- BDNF: Peprotech, Rocky Hill, NJ, USA
- GDNF: Peprotech, Rocky Hill, NJ, USA
- βNGF: Peprotech, Rocky Hill, NJ, USA
- Ascorbic acid: Sigma-Aldrich, St. Louis, MS, USA
- MEM NEAA

Cell culture small molecules:

- StemMACS™ Y27632: Miltenyi Biotec, Bergisch Gladbach, Germany
- CHIR99021: Axon Medchem, Groningen, Netherlands
- StemMACS™ SB431542: Miltenyi Biotec, Bergisch Gladbach, Germany
LDN193189

SU-5402

DAPT

Floxuridine

Chemicals, Buffers

0.5M EDTA

DPBS

DPBS+/−

PFA

Extracellular matrices

Matrigel, GFR

Matrigel, hESC qualified

Nucleic acid extraction kits

DNeasy Blood & Tissue Kit

miRNeasy Micro/Mini Kit

(qRT)-PCR reagents

Primers (see section 8.6)

One Taq® Hot Start DNA Polymerase w. Master Mix

TaqMan™ Universal PCR Master Mix

TaqMan™ Probes (see section 8.5)

StemPro® Accutase®

StemRNA™ 3rd Gen. Reprogramming Kit

Saponin

Toxin-labelling / Click chemistry

StxB

DkTx

STEMCELL Technologies, Vancouver, Canada

Sigma-Aldrich, St. Louis, MS, USA

Sigma-Aldrich, St. Louis, MS, USA

Santa Cruz Biotechnology, Dallas, TX, USA

Thermo Fisher Scientific, Waltham, MA; USA

Biochrom, Berlin, Germany

Sigma-Aldrich, St. Louis, MS, USA

Electron Microscopy Sciences, Hatfield, PA; USA

Corning, Corning, NY, USA

Corning, Corning, NY, USA

Qiage, Hilden, Germany

Qiage, Hilden, Germany

Sigma-Aldrich, St. Louis, MS, USA

New England BioLabs, Ipswich, MA, USA

Thermo Fisher Scientific, Waltham, MA; USA

Thermo Fisher Scientific, Waltham, MA; USA

Thermo Fisher Scientific, Waltham, MA; USA

ReproCELL, Yokohama, Japan

Sigma-Aldrich, St. Louis, MS, USA

Sigma-Aldrich, St. Louis, MS, USA

MyBioSource.com, San Diego, CA, USA
8.3 Buffers and solutions

Table 5: Buffers and solutions

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Final concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lysis buffer</strong></td>
<td></td>
</tr>
<tr>
<td>NaOH</td>
<td>25 mM</td>
</tr>
<tr>
<td>EDTA</td>
<td>200 µM</td>
</tr>
<tr>
<td><strong>Neutralizing buffer</strong></td>
<td></td>
</tr>
<tr>
<td>Tris-HCl</td>
<td>40 mM</td>
</tr>
<tr>
<td><strong>Bath solution</strong></td>
<td></td>
</tr>
<tr>
<td>NaCl</td>
<td>180 mM</td>
</tr>
<tr>
<td>CaCl₂</td>
<td>1.8 mM</td>
</tr>
<tr>
<td>KCl</td>
<td>5.4 mM</td>
</tr>
<tr>
<td>MgCl₂</td>
<td>1 mM</td>
</tr>
<tr>
<td>HEPES</td>
<td>10 mM</td>
</tr>
<tr>
<td>Glucose</td>
<td>10 mM</td>
</tr>
<tr>
<td><strong>Pipette solution</strong></td>
<td></td>
</tr>
<tr>
<td>KCl</td>
<td>170 mM</td>
</tr>
<tr>
<td>MgCl₂</td>
<td>2 mM</td>
</tr>
<tr>
<td>EGTA</td>
<td>1 mM</td>
</tr>
<tr>
<td>HEPES</td>
<td>5 mM</td>
</tr>
<tr>
<td>ATP</td>
<td>1 mM</td>
</tr>
</tbody>
</table>

For abbreviations see page 94
8.4 Technical equipment

6 mm skin punch biopsy KAI, Solingen, Germany
Analog Vortex Mixer VWR, Radnor, USA
accu-jet® pro pipette controller BrandTech Scientific, Essex, CT, USA
Biosphere® Filter Tips Sarstedt, Nuernbrecht, Germany
Cameras / Detectors
   Axiocam 506 mono Carl Zeiss, Oberkochen, Germany
   Edge 5.5 PCO, Kelheim, Germany
   DFC3000G Leica Microsystems, Wetzlar, Germany
   DMC2900 Leica Microsystems, Wetzlar, Germany
   SPOT INSIGHT™ Diagnostic Instruments, Sterling Heights, MI, USA
Cell culture consumables
   6-Well plate Greiner Bio One, Frickenhausen, Germany
   12-Well plate Thermo Fisher Scientific, Waltham, MA, USA
   24-Well plate Thermo Fisher Scientific, Waltham, MA, USA
   48-Well plate Thermo Fisher Scientific, Waltham, MA, USA
   Centrifuge tubes (15 ml, 50 ml) Greiner Bio One, Frickenhausen, Germany
   Cryovials Greiner Bio One, Frickenhausen, Germany
   Filtropur S 0.2 syringe filter Sarstedt, Nürnbrecht, Germany
   Pipette (5 ml, 10 ml, 25 ml, 50 ml) Greiner Bio One, Frickenhausen, Germany
   T-25 TC flask Thermo Fisher Scientific, Waltham, MA, USA
Centrifuges
   Centrifuge 5417R Eppendorf, Hamburg, Germany
   Rotina 420R Hettich, Tuttlingen, Germany
Combittips advanced® 0.5 ml Eppendorf, Hamburg, Germany
Cryostat CM3050 Leica, Wetzlar, Germany
Flow cytometer
   FACSCanto™ II BD Bioscience, East Rutherford, NJ, USA
   LSR II BD Bioscience, East Rutherford, NJ, USA
Freezer comfort -20°C Liebherr, Biberach, Germany
Freezer TSX Series -80°C Thermo Fisher Scientific, Waltham, MA, USA
Glass ware
   Coverglass, high precision, Hartenstein, Würzburg, Germany
Coverglass, high precision
24x50 mm
Roth, Karlsruhe, Germany

Excitation light sources for microscopy
Colibri 7 LED
Zeiss, Oberkochen, Germany
EL6000
Leica Microsystems, Wetzlar, Germany
HXP 120 C
Zeiss, Oberkochen, Germany

Heracell™ VIOS 160i CO₂ incubator
Thermo Fisher Scientific, Waltham, MA, USA
Herasafe™ HS18 laminar flow hood
Heraeus, Hanau, Germany
MicroAmp® fast 96-well reaction plate
Applied Biosystems, Darmstadt, Germany
MicroAmp® adhesive film
Applied Biosystems, Darmstadt, Germany

Microscopes
Apotome 2
Zeiss, Oberkochen, Germany
Axio Imager M.2
Zeiss, Oberkochen, Germany
Axioptot 2
Zeiss, Oberkochen, Germany
CKX41
Olympus, Tokyo, Japan
Elyra S.1 SIM
Zeiss, Oberkochen, Germany
DMi8
Leica Microsystems, Wetzlar, Germany
DMI IL LED
Leica Microsystems, Wetzlar, Germany
LSM700
Zeiss, Oberkochen, Germany

Multipette® Stream
Eppendorf, Hamburg, Germany
NanoDrop™ One Spectrophotometer
Thermo Fisher Scientific, Waltham, MA, USA
Objectslides superfrost
Langenbrinck, Teningen, Germany
PapPen
Sigma-Aldrich, St. Louis, MS, USA
Parafilm® M
Bemis Company Inc, Oshkosh, USA
PCR Tubes 0,2 ml, 1,5 ml
Eppendorf, Hamburg, Germany

Pipettes
Research® plus
Eppendorf, Hamburg, Germany

Software
DNA Baser
Heracle BioSoft, Pitesti, Romania
FACSDiva
BD Bioscience, East Rutherford, NJ, USA
FlowJo v10
FlowJo, Ashland, OR, USA
GraphPad Prism 8
GraphPad Software, San Diego, CA, USA
Image J free v1.52i
National Institute of Health, Bethesda, MD, USA
LAS X
Office 2016
SPSS IBM version 26
ZEN Blue/Black Edition

Leica Microsystems, Wetzlar, Germany
Microsoft, Redmond, WA, USA
IBM, Ehningen, Germany
Zeiss, Oberkochen, Germany

Thermocycler
Peqstar
Primus 96
QuantStudio 3

Peqlab, Erlangen, Germany
Peqlab, Erlangen, Germany
Applied Biosystems, Darmstadt, Germany

For abbreviations see page 94

Tissue-Tek® Cryomold
Sakura, Staufen, Germany
8.5 qRT-PCR probes

Table 6: TaqMan probes.

<table>
<thead>
<tr>
<th>Gene/Target</th>
<th>Assay-ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>18S rRNA</td>
<td>Hs99999901_s1</td>
</tr>
<tr>
<td>PRPH</td>
<td>Hs00196608_m1</td>
</tr>
<tr>
<td>SCN9A</td>
<td>Hs01076699_m1</td>
</tr>
<tr>
<td>TRPV1</td>
<td>Hs00218912_m1</td>
</tr>
<tr>
<td>TUBB3</td>
<td>Hs00801390_s1</td>
</tr>
</tbody>
</table>

8.6 PCR cycling conditions and primers

Table 7: PCR experiment variables.

<table>
<thead>
<tr>
<th>Target</th>
<th>Sequence (5'-3')</th>
<th>Annealing temp.</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLA</td>
<td>Fw: CTGTAACCTCAAGAGAAGG</td>
<td>44°C</td>
</tr>
<tr>
<td>c.708G&gt;C</td>
<td>Rev: CATCCTGCTCTAAGTAC</td>
<td></td>
</tr>
<tr>
<td>(TK1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLA cDNA</td>
<td>Fw: ATTGATGCCAGACCTTTGC</td>
<td>54°C</td>
</tr>
<tr>
<td>Exon 5</td>
<td>Rev: GGGTCCTGATTGATGGAATTAC</td>
<td></td>
</tr>
<tr>
<td>(TK1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLA</td>
<td>Fw: ACAGGGCCACTTATCAC</td>
<td>53°C</td>
</tr>
<tr>
<td>c.1069C&gt;T</td>
<td>Rev: AAAGGTGGACAGGAAGTAG</td>
<td></td>
</tr>
<tr>
<td>(TK8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLA</td>
<td>Fw: CACAATTTAAGCAGCAGCAAC</td>
<td>51°C</td>
</tr>
<tr>
<td>c.568delG</td>
<td>Rev: GGACATGAATGGTGAAAATAAAGG</td>
<td></td>
</tr>
<tr>
<td>(TK9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mycoplasma</td>
<td>Fw: GGGAGCAAACAGCATTAGATACCT</td>
<td>55°C</td>
</tr>
<tr>
<td>sp.</td>
<td>Rev: TGCACCATCTGTCACTCTGTTAACCTC</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: GLA = α-galactosidase A
8.7 Antibodies for ICC/IHC/FACS

<table>
<thead>
<tr>
<th>Reactivity</th>
<th>Host</th>
<th>Company</th>
<th>Catalog #</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRN3A</td>
<td>Goat</td>
<td>Santa Cruz Biotechnology</td>
<td>sc-31984</td>
<td>1:50</td>
</tr>
<tr>
<td>FOXA2</td>
<td>Mouse</td>
<td>Santa Cruz Biotechnology</td>
<td>sc-374376</td>
<td>1:50</td>
</tr>
<tr>
<td>LAMP1</td>
<td>Mouse</td>
<td>DSHB</td>
<td>H4A3</td>
<td>1:100</td>
</tr>
<tr>
<td>Na\textsubscript{v} 1.8</td>
<td>Rabbit</td>
<td>Alomone Labs</td>
<td>ASC-016</td>
<td>1:200</td>
</tr>
<tr>
<td>NCAM::647</td>
<td>Mouse</td>
<td>BioLegend</td>
<td>362513</td>
<td>1:100</td>
</tr>
<tr>
<td>OCT3/4</td>
<td>Mouse</td>
<td>Santa Cruz Biotechnology</td>
<td>sc-5279</td>
<td>1:50</td>
</tr>
<tr>
<td>PAX6</td>
<td>Rabbit</td>
<td>BioLegend</td>
<td>901302</td>
<td>1:200</td>
</tr>
<tr>
<td>PRPH::488</td>
<td>Mouse</td>
<td>Santa Cruz Biotechnology</td>
<td>sc-377093</td>
<td>1:250</td>
</tr>
<tr>
<td>PRPH::647</td>
<td>Mouse</td>
<td>Santa Cruz Biotechnology</td>
<td>sc-377093</td>
<td>1:250</td>
</tr>
<tr>
<td>REA Control (S)-APC</td>
<td>Human</td>
<td>Miltenyi-Biotec</td>
<td>130-113-434</td>
<td>1:11</td>
</tr>
<tr>
<td>REA Control (S)-PE</td>
<td>Human</td>
<td>Miltenyi-Biotec</td>
<td>130-113-438</td>
<td>1:11</td>
</tr>
<tr>
<td>SM22A</td>
<td>Rabbit</td>
<td>Abcam</td>
<td>ab14106</td>
<td>1:100</td>
</tr>
<tr>
<td>SOX10</td>
<td>Mouse</td>
<td>Santa Cruz Biotechnology</td>
<td>sc-365692</td>
<td>1:100</td>
</tr>
<tr>
<td>SOX2</td>
<td>Mouse</td>
<td>R&amp;D Systems</td>
<td>MAB2018</td>
<td>1:200</td>
</tr>
<tr>
<td>SP::594</td>
<td>Rat</td>
<td>Santa Cruz Biotechnology</td>
<td>sc-21715 AF594</td>
<td>1:100</td>
</tr>
<tr>
<td>SSAE4-APC</td>
<td>Human</td>
<td>Miltenyi-Biotec</td>
<td>130-098-347</td>
<td>1:11</td>
</tr>
<tr>
<td>SSEA4</td>
<td>Mouse</td>
<td>R&amp;D Systems</td>
<td>MAB1435</td>
<td>1:100</td>
</tr>
<tr>
<td>TRA-1-60</td>
<td>Mouse</td>
<td>Merck Millipore</td>
<td>MAB4360</td>
<td>1:100</td>
</tr>
</tbody>
</table>
For abbreviations see page 94

Table 9: Secondary antibodies

<table>
<thead>
<tr>
<th>Reactivity</th>
<th>Host</th>
<th>Company</th>
<th>Catalog # + dye</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chicken-IgY</td>
<td>Donkey</td>
<td>Jackson Immunoresearch</td>
<td>703-165-155</td>
<td>1:100</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cy3</td>
<td></td>
</tr>
<tr>
<td>Chicken-IgY</td>
<td>Donkey</td>
<td>Jackson Immunoresearch</td>
<td>703-545-155</td>
<td>1:300</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>AF488</td>
<td></td>
</tr>
<tr>
<td>Goat-IgG</td>
<td>Donkey</td>
<td>Jackson Immunoresearch</td>
<td>705-165-147</td>
<td>1:100</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cy3</td>
<td></td>
</tr>
<tr>
<td>Mouse-IgG</td>
<td>Donkey</td>
<td>Jackson Immunoresearch</td>
<td>715-165-150</td>
<td>1:100</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cy3</td>
<td></td>
</tr>
<tr>
<td>Mouse-IgG</td>
<td>Donkey</td>
<td>Jackson Immunoresearch</td>
<td>715-605-150</td>
<td>1:300</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>AF647</td>
<td></td>
</tr>
<tr>
<td>Mouse-IgG</td>
<td>Donkey</td>
<td>Jackson Immunoresearch</td>
<td>715-005-150</td>
<td>1:150</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>No dye</td>
<td></td>
</tr>
<tr>
<td>Rabbit-IgG</td>
<td>Donkey</td>
<td>Jackson Immunoresearch</td>
<td>711-605-152</td>
<td>1:300</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>AF647</td>
<td></td>
</tr>
<tr>
<td>Rabbit-IgG</td>
<td>Donkey</td>
<td>Jackson Immunoresearch</td>
<td>711-545-152</td>
<td>1:300</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>AF488</td>
<td></td>
</tr>
</tbody>
</table>

For abbreviations see page 94
8.8 Characterization for the second clone of TK8 and TK9

Two additional clones were generated and characterized for TK8 (Figure 28), and TK9 (Figure 29).

**Figure 28: Characterization of TK8 clone 8.** (A) HDF were reprogrammed to (B) iPSC with ESC-like morphology. (C) No chromosomal aberrations were found and (D) robust expression of the pluripotency markers was confirmed. (E) > 82% of live, single cells coexpressed TRA-1-60 and SSEA4, with (F) the retained c.1069C>T mutation. (G) Directed differentiation of cells into all three germ-layers was successful. Scale bars: 200 µm (A, B); 50 µm (D, G). Acquired with DMI IL LED (A, B) and Apotome (D, G).
Figure 29: Characterization of TK9 clone 1. (A) HDF were reprogrammed to (B) iPSC with ESC-like morphology. (C) No chromosomal aberrations were found and (D) robust expression of the pluripotency markers was confirmed. (E) > 80% of live, single cells coexpressed TRA-1-60 and SSEA4, with (F) the retained c.68delG mutation. (G) Directed differentiation of cells into all three germ-layers was successful. Scale bars: 200 µm (A, B); 50 µm (D, G). Acquired with DMI IL LED (A, B) and Apotome (D, G).

Abbreviations for Figure 28 and Figure 29: Ctrl = control; DAPI = 4′,6-diamidino-2-phenylindole; ESC = embryonic stem cell; FOXA2 = forkhead box protein A2; HDF = human dermal fibroblasts; iPSC = induced pluripotent stem cells; OCT4 = octamer-binding transcription factor 4; PAX6 = paired box 6, SM22A = smooth muscle protein 22-alpha; SOX2 = sex determining region Y box 2; SSEA4 = stage specific embryonic antigen 4; TRA-1-60 = tumor resistance antigen 1-60
8.9 Marker expression of mature neurons of additional clones

One additional clone of TK8 and TK9 (Figure 30) were analyzed for sensory marker expression.

![Gene expression TK8 CI8](image)

![Gene expression TK9 CI4](image)

**Figure 30: Gene expression on mature neurons.** Neurons from (A) TK8 clone 8 and (B) TK9 clone 4 expressed TUJ1, PRPH, Nav 1.7 and TRPV1.
8.10 Myoplasma screening

TK1 (Figure 31 A), TK8, and TK9 (Figure 31 B) iPSC lines were analyzed for mycoplasma contamination. No signal at 300 bp shows the absence of mycoplasma contamination in conditioned medium of all cell lines.

**Figure 31: PCR for mycoplasma detection.** (A) From left to right: 100 bp DNA ladder, positive control, medium from TK1-iPSC. (B) From left to right: 100 bp DNA ladder, positive control, medium from TK8 Cl.6, TK8 Cl.8, TK9 Cl.1, TK9 Cl.4

Abbreviations: + = positive control; bp = base pairs;
9 Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/5i</td>
<td>2/5 inhibitor cocktail</td>
</tr>
<tr>
<td>AF-xxx</td>
<td>Alexa Fluor™-xxx</td>
</tr>
<tr>
<td>AP</td>
<td>action potential</td>
</tr>
<tr>
<td>APC</td>
<td>allophycocyanin</td>
</tr>
<tr>
<td>βNGF</td>
<td>β-nerve growth factor</td>
</tr>
<tr>
<td>BDNF</td>
<td>brain-derived neurotrophic factor</td>
</tr>
<tr>
<td>BRN3A, POU4F1</td>
<td>POU class 4 homebox 1</td>
</tr>
<tr>
<td>CDC20</td>
<td>cell division cycle 20</td>
</tr>
<tr>
<td>CGRP</td>
<td>calcitonin gene-related peptide</td>
</tr>
<tr>
<td>CLSM</td>
<td>confocal laser scanning microscope</td>
</tr>
<tr>
<td>CM</td>
<td>cardiomyocytes</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
</tr>
<tr>
<td>Ctrl</td>
<td>control</td>
</tr>
<tr>
<td>DAPI</td>
<td>4’,6-Diamidin-2-phenylindol</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco’s modified Eagle medium</td>
</tr>
<tr>
<td>(c)(g)DNA</td>
<td>(copy)(genomic)deoxyribonucleic acid</td>
</tr>
<tr>
<td>DMSO</td>
<td>dimethyl sulfoxide</td>
</tr>
<tr>
<td>DNMT3B</td>
<td>DNA methyltransferase 3 β</td>
</tr>
<tr>
<td>DPBS&lt;sup&gt;−&lt;/sup&gt;</td>
<td>Dulbecco’s Phosphate-Buffered Saline</td>
</tr>
<tr>
<td>DPBS&lt;sup&gt;++&lt;/sup&gt;</td>
<td>Dulbecco’s Phosphate-Buffered Saline with Mg&lt;sup&gt;++&lt;/sup&gt;, Ca&lt;sup&gt;++&lt;/sup&gt;</td>
</tr>
<tr>
<td>DPPA2</td>
<td>developmental pluripotency associated 2</td>
</tr>
<tr>
<td>DRG</td>
<td>dorsal root ganglion</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>αSTORM</td>
<td>direct stochastic optical reconstruction microscopy</td>
</tr>
<tr>
<td>ECM</td>
<td>extracellular matrix</td>
</tr>
<tr>
<td>EDTA</td>
<td>ethylenediaminetetraacetic acid</td>
</tr>
<tr>
<td>EGTA</td>
<td>egtazic acid</td>
</tr>
<tr>
<td>ERT</td>
<td>enzyme replacement therapy</td>
</tr>
<tr>
<td>ESRRB</td>
<td>estrogen related receptor β</td>
</tr>
<tr>
<td>EZH2</td>
<td>enhancer of zeste 2 polycomb repressive complex 2 subunit</td>
</tr>
<tr>
<td>FACS</td>
<td>fluorescence activated cell sorting</td>
</tr>
<tr>
<td>FBXO15</td>
<td>F-box Protein 15</td>
</tr>
<tr>
<td>FCS</td>
<td>fetal calf serum</td>
</tr>
<tr>
<td>FD</td>
<td>Fabry disease</td>
</tr>
<tr>
<td>FdU</td>
<td>floxuridine</td>
</tr>
<tr>
<td>FGF4</td>
<td>fibroblast growth factor 4</td>
</tr>
<tr>
<td>FOXA2</td>
<td>forkhead box protein A2</td>
</tr>
<tr>
<td>Gb3</td>
<td>globotriaosylceramide</td>
</tr>
<tr>
<td>Gb4</td>
<td>globotetrahexosylceramide</td>
</tr>
<tr>
<td>GDNF</td>
<td>glial cell-derived neurotrophic factor</td>
</tr>
<tr>
<td>GLA</td>
<td>alpha-galactosidase A</td>
</tr>
<tr>
<td>HDF</td>
<td>human dermal fibroblast</td>
</tr>
<tr>
<td>hESC, ES</td>
<td>human embryonic stem cell</td>
</tr>
<tr>
<td>ICC</td>
<td>immunocytochemistry</td>
</tr>
<tr>
<td>IENFD</td>
<td>intraepidermal nerve fiber density</td>
</tr>
<tr>
<td>Term</td>
<td>Description</td>
</tr>
<tr>
<td>-------------</td>
<td>------------------------------------------------------------------</td>
</tr>
<tr>
<td>IHC</td>
<td>immunohistochemistry</td>
</tr>
<tr>
<td>iPSC</td>
<td>induced pluripotent stem cells</td>
</tr>
<tr>
<td>Klf4</td>
<td>Kruppel-like factor 4</td>
</tr>
<tr>
<td>KO</td>
<td>KnockOut</td>
</tr>
<tr>
<td>KO-SR</td>
<td>KnockOut™ Serum Replacement</td>
</tr>
<tr>
<td>LIN28</td>
<td>Lin-28 homolog A</td>
</tr>
<tr>
<td>MEM NEAA</td>
<td>minimum essential medium non-essential amino acids</td>
</tr>
<tr>
<td>MET</td>
<td>Mesenchymal-epithelial transition</td>
</tr>
<tr>
<td>Na&lt;sub&gt;v&lt;/sub&gt;</td>
<td>voltage gated sodium channel</td>
</tr>
<tr>
<td>NCAM, CD56</td>
<td>neural cell adhesion molecule</td>
</tr>
<tr>
<td>NR6A1</td>
<td>nuclear receptor subfamily group A member 1</td>
</tr>
<tr>
<td>Oct4</td>
<td>octamer-binding transcription factor 4</td>
</tr>
<tr>
<td>PAX6</td>
<td>paired box protein 6</td>
</tr>
<tr>
<td>(qRT)(RT)-PCR</td>
<td>(quantitative real-time)(reverse transcription) polymerase</td>
</tr>
<tr>
<td>PE</td>
<td>phycoerythrin</td>
</tr>
<tr>
<td>PFA</td>
<td>paraformaldehyde</td>
</tr>
<tr>
<td>PNS</td>
<td>peripheral nervous system</td>
</tr>
<tr>
<td>PRPH</td>
<td>peripherin</td>
</tr>
<tr>
<td>(m)(mi)RNA</td>
<td>(messenger)(micro)ribonucleic acid</td>
</tr>
<tr>
<td>ROCK(i)</td>
<td>Rho-associated protein kinase (inhibitor)</td>
</tr>
<tr>
<td>RT</td>
<td>room temperature</td>
</tr>
<tr>
<td>SALL4</td>
<td>spalt like transcription factor 4</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>SCNxA</td>
<td>sodium voltage-gated channel alpha subunit X</td>
</tr>
<tr>
<td>SIM</td>
<td>structured illumination microscopy</td>
</tr>
<tr>
<td>SM22A</td>
<td>smooth muscle protein 22-alpha</td>
</tr>
<tr>
<td>SOX10</td>
<td>sex determining region Y-box 10</td>
</tr>
<tr>
<td>SOX2</td>
<td>sex determining region Y-box 2</td>
</tr>
<tr>
<td>SSEA4</td>
<td>stage-specific embryonic antigen-4</td>
</tr>
<tr>
<td>StxB</td>
<td>Shiga toxin 1, B subunit</td>
</tr>
<tr>
<td>TRA-1-60</td>
<td>tumor resistance antigen 1-60</td>
</tr>
<tr>
<td>TRPV1</td>
<td>transient-receptor potential cation channel subfamily V member 1</td>
</tr>
<tr>
<td>TUJ1</td>
<td>neuron-specific class III β-tubulin</td>
</tr>
<tr>
<td>UTF1</td>
<td>undifferentiated embryonic cell transcription factor 1</td>
</tr>
<tr>
<td>wt</td>
<td>wildtype</td>
</tr>
<tr>
<td>XCI</td>
<td>X-chromosomal inactivation</td>
</tr>
<tr>
<td>YF</td>
<td>Yamanaka factors</td>
</tr>
</tbody>
</table>
10 List of Figures and Tables

Figure 1: Reprogramming stages. .......................................................... 10
Figure 2: Classification of Gb3 accumulations ..................................... 24
Figure 3: Characterization of a female FD-iPSC line. ............................ 29
Figure 4: Gb3 accumulations in FD-cells from female subject. .............. 29
Figure 5: Genetic and transcriptomic analysis of TK1-FD-iPSC. ............... 30
Figure 6: Gb3 accumulations in skin cryosections. ............................. 31
Figure 7: Morphological changes during reprogramming. ...................... 32
Figure 8: Characterization of TK8 clone 6. ....................................... 35
Figure 9: Characterization of TK9 clone 4. ....................................... 36
Figure 10: Gb3 accumulations in male FD-iPSC. ................................. 37
Figure 11: Neuronal differentiation. .................................................. 38
Figure 12: Comparison of cytostatics. .............................................. 39
Figure 13: Key marker expression during neuronal differentiation. ........... 41
Figure 14: Key sensory marker expression. ...................................... 42
Figure 15: Labeling of TRPV1. ...................................................... 43
Figure 16: Gene expression of mature neurons. .................................. 44
Figure 17: Gb3 accumulations in iPSC-derived neurons. ....................... 46
Figure 18: Effect of ERT on young neurons. ..................................... 48
Figure 19: Effect of ERT on mature neurons. .................................... 49
Figure 20: Time dependent accumulation of Gb3 in TK8 neurons .......... 50
Figure 21: Time dependent accumulation of Gb3 in TK9 neurons ........... 51
Figure 22: Effect of TNF on Gb3 depositions. ................................... 52
Figure 23: Ca2+ imaging of TK8 neurons. ........................................ 53
Figure 24: Ca2+ imaging of TK9 neurons. ........................................ 54
Figure 25: Ca2+ imaging of Ctrl neurons. ....................................... 55
Figure 26: Patch clamp analysis of control, TK8, and TK9. .................... 57
Figure 27: dSTORM microscopy of control neurons ............................ 57
Figure 28: Characterization of TK8 clone 8. ..................................... 90
Figure 29: Characterization of TK9 clone 1. ..................................... 91
Figure 30: Gene expression on mature neurons. ................................ 92
Figure 31: PCR for mycoplasma detection. ....................................... 93

Table 1: Clinical data of subjects and control person .......................... 14
Table 2: Diversification of STxB accumulations ................................ 23
Table 3: Amount of analyzed neurons ............................................. 47
Table 4: Media for differentiation and maturation .............................. 80
Table 5: Buffers and solutions ....................................................... 83
Table 6: TaqMan probes

Table 7: PCR experiment variables

Table 8: Primary antibodies

Table 9: Secondary antibodies
11 Curriculum vitae
Publications

Peer reviewed journals; original articles


Poster presentations at international conferences:


Karl, F., Malzacher, T., Kreß, L., Klein, T., Saffer, N., Fey, P., Sommer, C., Groeber-Becker, F., Üçeyler, N. (2018). Extended use of diagnostic skin punch biopsies of SFN patients to multiply limited material for new in vitro tools to investigate small fiber pathology. 48th international meeting of the Society for Neuroscience, San Diego, USA


Klein, T., Günther, K., Sommer, C., Edelhofer, F., Üçeyler, N. (2017). Generation of patient-derived sensory neurons using iPSC and smNPC obtained from patients with Fabry disease. 9th international meeting Stem Cell Network North Rhine-Westphalia, Münster, Germany

Klein, T., Günther, K., Sommer, C., Edelhofer, F., Üçeyler, N. (2016). Patient-derived peripheral sensory neurons as possible disease model for Fabry pain. 11th international symposium EUREKA, Würzburg, Germany
13 Danksagung

Diese Arbeit wäre nicht möglich gewesen ohne die Unterstützung vieler Leute. Falls ich jemanden vergessen habe, war das keine Absicht und ich entschuldige mich prophylaktisch dafür!

Frau Prof. Dr. Nurcan Üçeyler: Vielen Dank für die Möglichkeit meine Doktorarbeit in diesem Bereich schreiben zu dürfen. Vielen Dank auch für das Vertrauen, das Du in mich setzt, ich habe sehr viel gelernt während dieser Zeit.

Mein weiterer Dank gilt auch den Mitgliedern meines Promotionskomitees, Herrn PD Dr. Robert Blum, Herr Prof. Dr. Erhard Wischmeyer und Frau Prof. Dr. Claudia Sommer für den (wissenschaftlichen) Austausch und Kritik im Rahmen der Reports, oder auch bei den Retreats.

Meinen Bürokollegen Dr. Franziska Karl, Dr. Lukas Hofmann, Christoph Erbacher möchte ich von Herzen für die angenehme Arbeitsatmosphäre danken, bei der der Spaß nie zu kurz gekommen ist und die mich stets bei wissenschaftlichen, aber auch bürokratischen Hürden gut beraten haben. Katharina Klug, danke für dein Engagment während deiner Masterarbeit und dem Teilen der Wochenenddienste! Für die Wochenenddienste auch vielen Dank an Max Breyer, Chiazor Maureen Bob-Anyeji, Anna Forster und v.a. Bettina Vignolo, die sich auch bereit erkärt hat tausende Neurone auszuzählen.

Danke auch an die vielen TAs aus der Klinik, die mich entweder direkt bei der wissenschaftlichen Arbeit unterstützt haben, oder für ausreichend Kaffeenachschub gesorgt haben! Daniela Urlaub, die mich bei der Zellkultur entlastet hat: DANKE!

Ohne die enge Kooperation mit dem Institut für Biophysik und Biotechnologie wären viele Versuche in dieser Arbeit nicht möglich gewesen. Vielen Dank hierfür an Herrn Prof. Dr. Markus Sauer und v.a. auch Jan Schlegel. Jan, Danke für die Unterstützung sowohl bei den Versuchen, als auch als Kumpel beim Feierabendbier. Dass aus einer Idee, geboren beim Bier, eine offizielle Kooperation mit Nachfolgeprojekt wird, wer hätte an dem Abend damit gerechnet… Danke, ich schulde dir so einiges!

Mein Dank geht auch an Frau Dr. Katharina Günther, die mich in die Methodik der iPSC eingelernt hat und doch öfters Recht hatte, als ich es anfangs wahrhaben wollte.
Nicht zuletzt möchte ich mich bei allen weiteren Freunden bedanken, die mich moralisch unterstützt haben!

Und zu guter Letzt gilt mein besonderer Dank natürlich meiner Familie, ohne die ich niemals an diesem Punkt stehen würde. **DANKE für alles!**